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I dedicate this thesis to my mother who died too young from cancer.
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Karin Margaretha Gilljam 
 
 
All informasjon om en organisme er lagret i vår arvestoff, DNA. DNA er et relativt 
ustabilt makromolekyl som konstant blir utsatt for farer som truer dets integritet, både 
fra omgivelsene og fra kjemiske prosesser inne i selve cellen. I tillegg kan baser 
spontant bli mistet uten noe form for påvirkning. Selve kopieringen av DNA, den 
såkalte DNA-replikasjonen er svært rask og er en kritisk prosess i cellen hvor mye kan 
gå galt. I tillegg kan ureparerte DNA-skader ved replikasjonen foreviges i form av 
mutasjoner. Mutasjoner i gener som koder for proteiner som regulerer cellens vekst og 
død kan resultere i ukontrollert cellevekst og dermed kreft. En av cellens strategier for å 
sikre effektiv og trygg replikasjon og reparasjon av DNA’et er å samarbeide ved å 
danne proteinkomplekser, hvorav PCNA ofte spiller en sentral rolle. PCNA sitter som 
en homotrimerisk ring rundt DNA-tråden som replikeres, og fungerer som en plattform 
for binding av mange proteiner. I tillegg til binding av DNA-replikasjonsproteiner, 
bindes også mange DNA-reparasjonsproteiner til PCNA, og sørger for effektiv 
reparasjon av skadet DNA både før og etter selve replikasjonen. I tillegg er PCNA 
involvert i DNA-syntese ved reparasjon som ikke er assosiert med replikasjon.  
 
I 1998 ble det funnet et motiv (en peptid-sekvens) som er ansvarlig for at mange 
proteiner bindes til PCNA, kalt PCNA Interacting Peptide (PIP). I artikkel 1 fant vi ved 
hjelp av blant annet fluorescerende proteiner og konfokal mikroskopi et nytt motiv som 
er viktig for proteiners binding til PCNA. Dette motivet fant vi først i det direkte 
alkyleringsreparasjons-proteinet; human AlkB homologue 2 og derfor kalte vi motivet 
AlkB homologue 2 PCNA Interacting Motif (APIM). I denne artikkelen verifiserer vi et 
funksjonelt APIM motiv i fem proteiner og viser at over-uttrykk av dette motivet gjør 
celler mer sensitive for alkylerende skade. Dette tyder på at overuttykk av APIM 
hemmer bindingen mellom APIM-inneholdende DNA reparasjons-proteiner og PCNA 
slik at de ikke reparerer DNA-skadene optimalt. 
 
I samme artikkel viser vi også at APIM er konservert i mer enn 200 proteiner, blant 
annet i nukleotideeksisjonsreparasjons (NER) proteinet Xeroderma Pigmentosum group 
A (XPA), og i artikkel 2 verifiserer vi at APIM også er et funksjonelt PCNA bindende 
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motiv i XPA. Vi viser og at overuttrykk av APIM-peptidet gjør celler mer sensitive for 
skade fra UV-lys, en type DNA-skade som hovedsakelig blir reparert av NER. I tillegg 
finner vi bevis som støtter at det er redusert funksjon av XPA som er årsak til at cellene 
er mer UV-sensitive ved overuttrykk av APIM, antagelig pga. svekket binding til PCNA. 
 
I artikkel 3 ser vi nærmere på baseeksisjonsreparasjons- og singeltrådbrudds-
reparasjons-proteinet XRCC1. Dette er i likhet med PCNA og XPA et protein uten 
enzymatisk funksjon, men med mange bindingspartnere, blant annet PCNA. Hvilken del 
av XRCC1 som er viktig for dens funksjon i cella er derimot ikke helt klarlagt, noe vi 
undersøker nærmere i denne artikkelen. Det viser seg at den delen av XRCC1 som har 
evnen til å binde PCNA og alkyleringsreparasjons-proteinet MPG er den eneste XRCC1 
mutanten som kan stimulere reparasjon av alkyleringsskader, noe som igjen bekrefter 
viktigheten av å binde seg til PCNA.  
 
Oppsummert tar dette arbeidet for seg hvordan DNA-reparasjonsproteiner binder seg til 
hverandre og PCNA, og hvordan dette påvirker evnen til å reparere DNA og dermed 
tåle DNA-skade.  
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ABBREVIATIONS 
 
A  Adenine 
A  Alanine, Ala 
2OG   2-oxoglutarate 
AAG  3-alkyladenine DNA glycosylase 
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dRP  Deoxyribosephosphate  
dRPase  Deoxyribosephosphate phosphodiesterase 
ds  Double strand 
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DSBR   Double strand break repair 
F  Phenyl alanine 
FA   Fanconi anemia 
FEN1   Flap endonuclease 1 
FRET  Fluorescence resonance energy transfer 
FTO   Fat mass and obesity associated protein 
G  Guanine 
GGR  Global genome nucleotide excision repair 
GFP  Green fluorescent protein 
HeLa  Henrietta Lacks 
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HNPCC  Hereditary non-polyposis colon cancer 
HR   Homologous recombination 
HR23B  Homologue of yeast Rad23 
HU  Hydroxy urea 
ICL   Interstrand crosslink 
IR  Ionizing radiation 
MBD4   Methyl-binding domain glycosylase 4 
meA   Methyladenine 
meC   Methylcytosine 
meG   Methylguanine 
meT   Methylthymine 
MGMT   O6-methylguanine DNA methyltransferase 
MMR   Mismatch repair 
MMS   Methyl methanesulphonate 
MPG   N-methylpurine DNA glycosylase 
MRN   MRE11/RAD50/NBS1 
MSH  MutS homologue 
MLH  MutL homologue 
MYH  mutY homologue 
NEIL2  Nei endonuclease VIII-like 2 
NER   Nucleotide excision repair 
NHEJ   Non-homologous end joining 
NLS  Nuclear localization signal 
OGG  8-oxoguanine DNA glycosylase 
OH  Hydroxyl 
p21  Cyclin-dependent kinase inhibitor 
PCNA  Proliferating cell nuclear antigen 
PIP  PCNA interacting peptide 
PMS2  Post-meiotic segregation 2 
PNK  Polynucleotide kinase 3’-phosphatase 
Pol    Polymerase 
Pro-BRE BRCA1/2-containing complex subunit 
ROS   Reactive oxygen species 
RPA  Replication protein A 
SAM   S-adenosylmethionine 
SCAN1  Spinocerebellar ataxia with axonal neuropathy 1 
SNP  Single-nucleotide polymorphism 
SMC5  Structural maintenance of chromosomes 5 
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S-phase  Synthesis-phase 
ss   Single stranded 
SSB   Single strand break 
SSBR  Single strand break repair 
T  Thymine 
TCR  Transcription coupled nucleotide excision repair 
TFIIH  Transcription factor II H 
TFII-I  Transcription factor II-I 
TFIIS-L  Transcription factor II S-Like 
TDP1  Tyrosyl DNA phosphodiesterase 
Topo Topoisomerase 
TLS   Translesion synthesis 
TTD  Trichothiodystrophy 
UDG   Uracil-DNA glycosylase 
UNG   Uracil-DNA glycosylase 
UV  Ultra violet 
W  Tryptophan, Trp 
Y  Tyrosine, Tyr 
YFP  Yellow fluorescent protein 
XAB1/2  XPA-binding protein 1/2 
XLF  XRCC4-like factor 
XP   Xeroderma pigmentosum 
XPA-G  Xerodemra pigmentosum group A-G 
XPV  Xeroderma pigmentosum variant 
XRCC1  X-ray repair cross-complementing protein 1 
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INTRODUCTION 
Keeping the genome intact is a challenge due to the unstable nature of DNA and the 
threat from endogenous and environmental agents. The acute effects of DNA damage 
are cell cycle arrest, transcription block, and apoptosis, but DNA damage left unrepaired 
may result in mutations. From an evolutionary perspective, mutations are essential for 
generation of genetic variation, however, with respect to human health, mutations are 
harmful as they are the driving force for oncogenesis, leading to the formation of cancer.   
DNA replication  
DNA replication is a critical event in the cell; errors can be made and importantly, DNA 
damage unrepaired upon DNA replication may give rise to mutations. Thus, many DNA 
repair proteins interact with the replication machinery in order to be at the right place at 
the right time. 
All organisms must duplicate their entire DNA before the cell can divide. In mammals, 
DNA replication occurs at a polymerisation rate of 20-50 nucleotides per second 
(Burgers, 2009). The mammalian genome consists of 3 × 109 base pairs, but only 1 error 
in every 109 base pair is made (Alberts, 1994). To achieve such low error-rate during 
the rapid polymerization, mechanisms for reliable and efficient DNA replication have 
evolved: The DNA polymerases catalyze a nucleophilic attack on the 3’ hydroxyl (OH) 
terminus from the sugar backbone only when the base on the incoming nucleotide is 
complementary, i.e. forms a Watson-Crick base pair with the opposite base (Stryer, 
1995). Furthermore, the few errors made by the replicative polymerases are repaired by 
the 3’ to 5’ exonuclease proofreading activity within the polymerase itself (Alberts, 
1994). Finally, many proteins participate in the formation of large replication protein 
complexes, in order to ensure efficient and reliable DNA duplication.  
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Since the DNA polymerases attack the 3’ terminus and both strands serve as templates, 
the so-called replication fork is asymmetrical. One strand, the leading strand, is 
continuously duplicated, while the opposite, the lagging strand, is discontinuously 
duplicated. Despite the differences of the two strands, they are held together by large 
multiprotein complexes that move rapidly along the DNA. For the leading strand, Pol ε 
is suggested to be responsible for the continuous polymerization, at least in yeast 
(Pursell et al., 2007). For the lagging strand, however, there is a constant need of RNA 
primers formed by the Pol α/primase. Pol α elongates the RNA primers for a few 
nucleotides, and is replaced by Pol δ. Pol δ continues polymerization until it runs into 
the next RNA primer. Pol δ displaces the RNA, and the flap is cleaved off by Flap 
endonuclease I (FEN1) followed by sealing of the gap by DNA ligase I (LIG1) (Burgers, 
2009). Other proteins involved in the replication machinery complex are: Replication 
protein A (RPA) which stabilizes the ssDNA; DNA helicase which unwinds the 
template; and topoisomerases which reveal the supercoil. Importantly, the proliferating 
cell nuclear antigen (PCNA) forms a sliding clamp around DNA, constituting a platform 
for binding and organization of the DNA polymerases, FEN1, LIG1 and more (Bowman 
et al., 2004; Maga and Hubscher, 2003). Many core replication proteins bind to PCNA 
through a conserved motif called the PCNA interacting peptide (PIP) box (Warbrick, 
2000), discussed later. The replicating protein complex is illustrated in figure 1. 
 
Figure 1: Cartoon of the replication fork. 
Black lines illustrate the template DNA, the 
grey lines the newly formed DNA and the 
purple lines the RNA primers. 
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There are essentially two forms of topoisomerases solving the topological problems 
caused by the DNA unwinding during replication, Topoisomerase (Topo) I and II. Topo 
I cuts one strand while Topo II cuts both strands and can therefore be a threat to the cell 
as it has the potential to cause lethal double strand breaks (DSBs) (Agostinho et al., 
2004; Nitiss, 2009a). The positive supercoiled DNA can be relaxed by either Topo I or 
Topo II in front of the replication fork as illustrated in figure 1. However, only Topo II 
seems to be able to solve the topological problem in late S-phase by decatenation. When 
two replication forks meet, completion of replication leads to formation of two 
interlinked catenanes (figure 2). Resolution of this catenan requires Topo II. There are 
two isoforms of Topo II, called Topo II α and β, where Topo II α appears to be essential 
for cell survival (Agostinho et al., 2004). In addition to replication, Topo II also has a 
pronounced role in chromosome separation and transcription which encounter similar 
topology issues (Nitiss, 2009a).  
 
 
Figure 2: Resolving of topological problems including decatenation 
by Topo II. Adapted from (Nitiss, 2009a). 
 
Topo II α is one of the proteins containing the newly identified PCNA interaction motif; 
AlkB homologue 2 PCNA interacting motif (APIM), published in paper 1. Topo II α 
has previously been suggested to interact with PCNA through a PIP-box like sequence 
(Niimi et al., 2001); however, our studies indicate that it is the APIM motif, rather than 
the proposed PIP-box, that is responsible for the interaction between Topo II α and 
PCNA. 
Topo I 
Topo II 
 
Topo II 
Supercoiled Relaxed, 
decatenated 
Catenanes 
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Proliferating cell nuclear antigen 
PCNA consists of three similar subunits forming a donut with an overall negative 
charge. The inner surface; however, is positively charged due to many lysine and 
arginine residues, enabling DNA to pass through the donut without electrostatic 
repulsions. PCNA consists of a “front” and a “back” side, and it is suggested that PCNA 
forms a double trimer with a back-to-back interaction (Naryzhny et al., 2005). The level 
of PCNA molecules is cell cycle regulated and reaches a peak during S-phase. The 
average number of PCNA molecules in a normal cell is 500 000 monomers. However, 
in a rapidly dividing cancer cell, the average is 4 000 000 PCNA molecules (Naryzhny, 
2008). PCNA has therefore been suggested as a prognostic marker for cancer (Naryzhny, 
2008; Stoimenov and Helleday, 2009). 
Numerous proteins bind to PCNA, and all identified protein - PCNA interactions are on 
the “front” side of PCNA (Jonsson et al., 1998). Many proteins bind through the 
conserved PIP-box (Qxx(L/I/M)xx/(F/Y)(F/Y)) identified in 1998 (Warbrick, 1998). 
Since then, a second PCNA binding motif, termed the KAx-box, was suggested (Xu et 
al., 2001); however, the biological significance of this motif is not verified. In 2009 we 
identified a new PCNA binding motif, first identified in the AlkB homologue 2, thereby 
its name APIM: AlkB homologue 2 PCNA Interacting Motif. This motif is functionally 
verified in six human proteins and a conserved motif is found in more than 200 other 
proteins. The discovery of this motif is described in paper 1.  
PCNA plays important roles in many cellular processes in addition to DNA replication. 
These include involvement in regulation of replication bypass, prevention of sister 
chromatid recombination, DNA repair, chromatin remodeling and epigenetics, sister 
chromatin cohesion, cell cycle control and cell survival (Moldovan et al., 2007). With 
such diverse roles, and with a growing number of binding partners, a tight regulation is 
needed. This regulation occurs at several levels; one level is through different affinity to 
PCNA for proteins which bind to the same part of PCNA. An example of this is the 
PIP-containing protein cyclin-dependent kinase inhibitor 1 (p21) which interacts with 
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PCNA with a higher affinity than other PIP-box containing proteins. The PCNA - p21 
binding thereby result in replication arrest by blocking the binding of Pol ε and δ to 
PCNA (Podust et al., 1995). Also, post translational modifications (PTMs) on either 
PCNA or its binding partners can regulate the affinity. PCNA ubiquitylation is the most 
documented PTM on PCNA and is involved in the polymerase switch in translesion 
synthesis described later (Lee and Myung, 2008; Moldovan et al., 2007). Furthermore, 
PCNA is reported to be SUMOylated, phosphorylated, acetylated and deacetylated 
(Hoege et al., 2002; Naryzhny and Lee, 2004; Prosperi et al., 1994). Also, a cancer 
specific modification on PCNA; methyl esterification, has been identified (Hoelz et al., 
2006). PCNA is also know to be proteolyzed, but the biological relevance of this is 
unclear (Naryzhny, 2008). The PCNA form which binds to the APIM motif seems to 
have a PTM modification; however, the nature of this modification is not known (paper 
1). 
Numerous PCNA molecules, replication factors, cell cycle regulating proteins, DNA 
repair proteins etc. cluster to form so-called replication factories in the nucleus. These 
clusters give foci which can be visualized by fluorescent microscopy. When PCNA is 
fused to a fluorescent protein such as Green fluorescent protein (GFP) these foci can 
also be detected in live cells and this has been employed in the work for this thesis. In 
early S-phase the foci are small and localized throughout the nucleus, in mid S-phase 
the foci localize around the nucleoli and close to the membrane, and in late S-phase the 
foci are large and localized around the nucleoli (Leonhardt et al., 2000).   
DNA damage 
Damage to our DNA happens continuously, both by spontaneous reactions, most 
frequently from reactions with oxygen and water, and by influence from endogenous 
and exogenous agents. Quantitatively, most damage occurs as a result of spontaneous 
reactions and from endogenous agents, however, exogenous agents also pose a threat to 
the genome integrity. The exogenous agents include different chemicals that severely 
damage the DNA, including chemicals used in chemotherapy for cancer patients  
 16
Endogenous DNA damage  
Reactive oxygen species (ROS) are generated during normal cellular metabolism and 
are among the most important sources of endogenous damage (De Bont and van 
Larebeke, 2004). The superoxide anion radical (·O2-) is abundant in the cell, but its 
reactivity is low. ·O2- can, however, be converted to hydrogen peroxide (H2O2) by 
superoxide dismutase, which in turn can be reduced to the extremely reactive hydroxyl 
radical (·OH). Hydrogen peroxide is used as a source for generation of oxidative 
damage in paper 3. The DNA damage from ROS includes oxidized bases, single strand 
breaks (SSBs) and DSBs (De Bont and van Larebeke, 2004). Furthermore, oxygen 
radicals can abstract electrons from organic macromolecules such as lipids in a reaction 
called lipid peroxidation. The oxidized lipid products react with DNA and can result in 
the severe crosslinking between opposite DNA strands, so-called interstrand crosslinks 
(ICLs) (Friedberg, 2006). 
Alkylating agents are electrophilic compounds with affinity for nucleophilic centers in 
organic macromolecules (Friedberg, 2006). They may arise from endogenous and 
exogenous sources and are widely used in cancer treatment. The main source of 
endogenous alkylation is S-adenosylmethionine (SAM), a small molecule with a 
reactive methyl group. SAM is involved in execution of physiologically enzymatic 
DNA methylation which is important in gene expression regulation. However, due to its 
reactivity, mutagenic and cytotoxic adducts can also be formed (De Bont and van 
Larebeke, 2004).   
The glycosidic bond between the base and the deoxyribose is labile under certain 
conditions and may be cleaved off forming apurinic/apyrimidinic (AP) sites. This 
process can occur both spontaneously or as a consequence of ROS, and constitutes one 
of the most frequent lesions in DNA with 10 000 to 20 000 estimated AP sites per cell 
per day (Friedberg, 2006). The AP sites are cytotoxic as they stall replication and may 
lead to collapse of the replication fork forming DSBs. AP sites are also mutagenic, as 
the polymerase lacks a template, thus a random base is inserted, which in 54% of the 
incidents are adenines (De Bont and van Larebeke, 2004; Lawrence et al., 1990). 
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Hydrolytic deamination occurs more frequently in ssDNA than in dsDNA, and more 
frequently of pyrimidines than of purines. 100 to 500 cytosines per cell per day are 
estimated to deaminate forming uracil (De Bont and van Larebeke, 2004). Uracil, not 
normally present in DNA, resembles thymine and forms a base pair with adenine during 
replication. Thus, deaminated cytosines in DNA are mutagenic as they give C:G to T:A 
transition mutations. Uracil may also be mis-incorporated during DNA synthesis as 
substitute for thymine. In this case, uracil will not be directly mutagenic; however, the 
AP sites generated during removal of these uracils may be potentially mutagenic and 
cytotoxic (De Bont and van Larebeke, 2004; Friedberg, 2006). 
Exogenous DNA damage 
In general, exogenous DNA damage is more bulky than endogenous DNA damage, and 
is the main source for DSBs (De Bont and van Larebeke, 2004). Damage to DNA 
caused by ultraviolet (UV) light irriadiation was the first template for study of DNA 
repair (Friedberg, 2006). The UV light is divided into UV-A (320-400 nm), UV-B (295-
320 nm) and UV-C (100-295 nm). The DNA absorption peak is at 260 nm (UV-C 
specific), however, not much UV-C radiation reaches the earth since wavelengths below 
300 nm have low penetration through ozone. Thus, the solar UV light at the earth 
mainly consists of UV-A and UV-B (Cadet et al., 2005; Pfeifer et al., 2005). UV-B 
(used in the work for paper 2) and UV-C mostly induce DNA damage directly by 
covalent linkage between adjacent pyrimidines, forming most frequently cyclobutane 
pyrimidine dimers (CPDs), and to a smaller extent (6-4) photoproducts (Yoon et al., 
2000) (illustrated in figure 3). Particularly the (6-4) photoproducts, but also the CPDs 
distort the DNA helix and both interfere with DNA replication (Kaufmann, 2007). UV-
A radiation is not readily absorbed by DNA and mostly damages DNA indirectly 
through formation of reactive species, most frequently by formation of ROS (Cadet et 
al., 2005; Pfeifer et al., 2005).  
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Figure 3: Cartoon of the most common DNA damage 
from UV; Cyclobutane pyrimidine dimer (CPD) and (6-
4) photobroduct. Adapted from (Cadet et al., 2005). 
 
Ionizing radiation (IR) is naturally occurring cosmic radiation, and has always been 
present. Damage from IR can take place either through direct absorption of the radiation 
energy by DNA, or indirectly as for the UV damage. IR may damage the base and form 
strand breaks (Friedberg, 2006). Moreover, DNA can be damaged by a wide range of 
chemicals. In addition to the chemotherapeutic anti-cancer drugs, carcinogenic 
chemicals are present in pollution, food, industrial waste, tobacco smoke, and more 
(Poirier, 2004).  
Anti‐cancer chemotherapy 
The aim of anti-cancer therapy is to kill the cancer cells more efficiently than normal 
cells. To achieve this, cancer therapy must exploit the molecular and cellular features, 
characteristic for the target cancer cells. Since most cancer cells have a higher 
proliferation rate than normal cells, most cancer drugs target the cell cycle. Entry into 
the cell cycle can be inhibited by hormonal manipulation, therapeutic antibodies or 
drugs that inhibit the growth signals (Helleday et al., 2008). However, the use of DNA 
damaging chemotherapy which inhibits the cell cycle is more common and will be 
emphasized in this thesis. There are many cancer drugs, and the main groups are listed 
in table 1. Their general trait is their ability to produce excessive amounts of DNA 
damage causing cell death, either directly or following DNA replication.  
Cyclobutane pyrimidine dimer         (6-4) photoproduct 
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Table 1: The main groups of anti-cancer chemotherapy and the various lesions 
they may form. Modified from (Helleday et al., 2008). * Chemotherapy used in the 
work for this thesis. 
 
ANTI‐CANCER CHEMOTHERAPY  DNA LESION 
Radiotherapy and radiomimetics 
Ionizing radiation 
Bleomycin  
Single‐strand breaks 
Double‐strand breaks 
Base damage 
Monofunctional alkylators 
Alkylsuphonates 
Nitrosurea compounds 
Temozolomide * 
Base damage 
Bulky adducts 
Bifunctional alkylators 
Nitrogen mustard 
Mitomycin C * 
Carmustine/BCNU * 
Cisplatin (*) 
Double‐strand breaks 
DNA crosslinks 
Bulky adducts 
Antimetobolites 
5‐Fluorouracil 
Hydroxyurea 
Folate analogues 
Base damage 
Replication lesions 
Topoisomerase inhibitors 
Camptothecins 
Etoposide 
Double‐strand breaks 
Single‐strand breaks 
 
 
Inhibitors of DNA replication impair replication fork progression which may cause 
DNA lesions including DSBs, and are therefore regarded as DNA damaging agents. 
Antimetabolites interfere with DNA replication by inhibiting nucleotide metabolism 
pathways, thereby depleting the cells of deoxyribonucleotides (dNTPs), or by being 
incorporated into the DNA. One of these antimetabolites, hydroxyurea (HU) is a 
clinically important anti-cancer drug and is also commonly used in the laboratory for 
study of arrested replication forks. HU acts by inhibiting the enzyme ribonucleotid 
reductase, preventing the conversion of ribonucleotides into dNTPs, thereby depleting 
the cells for dNTPs and stalling replication (Saban and Bujak, 2009). Inhibitors of the 
topoisomerases exploit the naturally occurring strand breaks. As already mentioned, 
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Topo I introduces SSBs and Topo II introduces DSBs while resolving torsional strains 
during DNA replication. Inhibitors of Topo I cause positive supercoils in front of the 
replication forks and replication associated DSBs, whereas inhibitors of Topo II trap the 
enzyme in complex with DNA leaving DSBs (Nitiss, 2009b; Pommier, 2006).  
Alkylating agents are the oldest group of anti-cancer drugs, and remain among the most 
important group of chemotherapeutics in cancer treatment. In fact, alkylating drugs 
were first introduced as mustard gas during World War I as an agent for chemical 
warfare. Unexpectedly, beneficial traits of this horrifying drug were observed by the US 
Chemical Defense Research Department (Biesele et al., 1950). They found that the 
mustard gas interfered with mitosis and gave chromosomal aberrations, and by 
dissolving mustard gas in alcohol in the late 1920s, the first anti-cancer cytostatic with 
promising effect on superficial tumors was invented (Biesele et al., 1950; Joensuu, 
2008). Although this drug was abandoned from clinical use, it constituted the 
foundation for future research resulting in the crosslinking alkylators used today.  
Alkylating drugs exert their cytotoxic effect by modifying the DNA bases by covalently 
binding to DNA, either directly or after being metabolized in the body. The alkylating 
agents can be either monofuncitonal, with one reactive site modifying single bases, or 
bifunctional, with two reactive sites, capable of crosslinking two DNA bases in the 
same (intra-) or the opposite (inter-) strand. Temozolomide used in paper 1 is an 
example of a monofunctional alkylator. Temozolomide is believed to introduce methyl 
adducts on N7G and O6G, with the O6meG as the most toxic lesion, inhibiting the DNA, 
RNA, and protein synthesis (Marchesi et al., 2007). The alkylators Mitomycin C, used 
in paper 1, and cisplatin mentioned in paper 2 are examples of bifuncional agents and 
are frequently used in treatment of several malignancies. Cisplatin has no alkyl group, 
but its mechanism is similar to that of alkylating drugs. Cisplatin primarily forms 
adducts on GG resulting in intrastrand crosslinks (95%). However, the minor ICLs are 
believed to constitute its anticancer effect by forming a total block of the DNA 
synthesis, thus interfering with the cell cycle (Chaney et al., 2005; Siddik, 2003; Wang 
and Lippard, 2005).  
 21
Cellular response to DNA damage 
DNA damage can be both mutagenic and cytotoxic to the cell. Left unrepaired upon 
DNA replication, damage to DNA can give rise to mutations, and accumulation of 
mutations in genes coding for proteins involved in the cell’s regulation of growth and 
death may in the worst case give rise to immortal cancer cells. DNA damage may also 
impair the protein synthesis, arrest the cell cycle, and lead to cell death - thus the 
cytotoxicity of the DNA damage. To render life possible, cells have evolved a natural 
defense to combat these threats. One of these defenses is through DNA repair, which 
counteracts most of the DNA damage before they harm the cells. 
DNA repair  
Traditionally, DNA repair has been divided into distinct pathways, such as lesion 
bypass, mismatch repair, direct repair, nucleotide and base excision repair, single and 
double strand break repair and the newly identified Fanconi anemia (FA) pathway. 
Recent research has, however, shown that the pathways are not always distinct and 
crosstalk between the different repair pathways is common. This is demonstrated by the 
Fanconi anemia (FA) ICL repair protein; FANCD1, which is identical to the DSB repair 
protein; breast and ovarian cancer type 2 susceptibility protein (BRCA2) (Wang, 2007). 
In the work for the papers presented in this thesis, we have studied the repair efficiency 
and damage tolerance after induction of certain types of DNA lesions. Most DNA 
lesions can be repaired by several DNA repair pathways, thus; in this thesis, the repair is 
described dependent on which type of DNA damage is repaired. Also, many DNA 
repair pathways are involved in the repair of more than one type of DNA damage, and 
will be briefly described the first time mentioned. To simplify, the focus will be on 
human, nuclear DNA repair. Proteins involved in direct repair as well as nucleotide and 
base excision repair are studied in paper 1, 2 and 3 respectively. Common for all three 
papers, however, is the importance of complex formation, especially with the “Maestro 
of the replication fork” PCNA.  
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Repair of damaged bases and single strand breaks 
DNA damage from endogenous impact such as ROS and alkylation as well as 
spontaneous hydroxylation causes loss or damage of the DNA base. Loss of the base 
resulting in AP sites has the potential to form single strand breaks (SSBs). This kind of 
DNA damage is predominantly repaired by the base excision repair (BER)/single strand 
break repair (SSBR) pathways, however, mechanisms of direct reversal of the damaged 
base, such as bases alkylated by SAM, are also important. Moreover, the mismatch 
repair (MMR) pathway, normally regarded as a repair pathway for mis-incorporated 
bases, is involved in the repair of certain types of base damage.  
Mismatch repair 
The main function of MMR is to execute post-replicative repair of errors that have 
escaped the 3’- 5’ exonucleolytic proofreading activity by replicative DNA polymerases, 
but it can also recognize base damage such as O6meG caused by the anti-cancer drug 
temozolomide used in paper 1. Mis-incorporated bases are identified due to their failure 
to form Watson-Crick base pairs, while the base damage is identified due to a weakened 
base pairing as well as a slightly distorted helix (Dalhus et al., 2009). Mis-incorporated 
bases can give rise to mutations, while the methylated guanine can form base pairs with 
both cytosine and thymine; however, both meG:C and meG:T recruits the MMR 
machinery (Jiricny, 2006; Jun et al., 2006).  
There are still some disputes regarding the exact mechanisms for MMR. However, it is 
commonly agreed that base - base mispairs and small insertion/deletion loop mispairs 
are recognized by a heterodimer of MutS homologues MSH2 and MSH6 (also-called 
MutSα), whereas a heterodimer containing MSH2 and MSH3 (also-called MutSβ) 
recognizes larger insertion/deletion loop mispairs (Jiricny, 2006; Jun et al., 2006). The 
MutSα or β complex binds to the mismatch and recruits a second heterodimer composed 
of two MutL homologues; MLH1 and post-meiotic segregation 2 (PMS2) (also-called 
MutLα). MutSα/β and MutLα are converted into sliding clamps by an ATP-driven 
conformation switch. The MutSα/β and MutLα complexes translocate in both directions 
in search for strand discontinuity. EXO1, a 5’ to 3’ exonuclease, subsequently binds 
 23
MSH2 and MLH1 (Jager et al., 2001; Tishkoff et al., 1998). This complex is believed to 
degrade a stretch of several hundred nucleotides, while RPA stabilizes the ssDNA. The 
degeneration ceases as the complex encounters the miss-pair. Replicative DNA 
polylmerases can then resyntesize the degraded region and DNA ligase seals the nick 
(Genschel and Modrich, 2003; Jiricny, 2006; Jun et al., 2006). Since only the newly 
synthesized strand is degraded, damaged bases such as O6meG are not removed. Instead, 
MMR is believed to act as a damage sensor, signaling cell cycle arrest due to the so-
called futile cycle, leaving other repair pathways to remove the damage (Jiricny, 2006; 
Meyers et al., 2003). The futile cycle is a result of MMR removal of the mismatch 
leaving the damaged base intact. The remaining lesion makes the MMR pathway to 
restart again and again, leading to cell cycle arrest. This allows time for other DNA 
repair mechanisms to remove the erroneous base, or alternatively formation of strand 
breaks and subsequently cell death (Jiricny, 2006; Meyers et al., 2003). 
PCNA appears to function at several steps in MMR. It is essential from the start during 
mismatch recognition by binding to MSH3 and MSH6 (Flores-Rozas et al., 2000; Iyer 
et al., 2008; Kleczkowska et al., 2001), during translocation by binding of MLH1 (Lee 
and Alani, 2006), during digestion by binding to EXO1 (Nielsen et al., 2004), and 
throughout the completion of the repair pathway by binding the polymerase during 
DNA resynthesis (Moldovan et al., 2007). Notably, MSH3, MSH6 and MLH1 contain 
the conserved PIP-box motif (Kleczkowska et al., 2001; Lee and Alani, 2006). The 
importance of PCNA in the MMR pathway was demonstrated by Clark and colleagues 
by mutating the PIP-box in MSH6, which resulted in increased mutation rate (Clark et 
al., 2000). When using a p21 peptide which binds PCNA tightly by its PIP-box, the 
binding site on PCNA for other PIP-box containing proteins is blocked (Podust et al., 
1995). This was utilized by Maish and colleagues who found that p21 prevents the 
binding of the MMR factors to the replication fork, demonstrating that PCNA is 
required for recruitment of the MMR machinery (Masih et al., 2008). 
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Direct repair 
Direct repair is a mechanism for removing the lesion, without removing the nucleotide. 
There are essentially two mechanisms of direct repair of alkylated bases in humans, 
repair by transfer and by oxidative demethylation. In humans, there is one alkyl 
transferase called O6-methylguanine-DNA methylatransferase (MGMT) also-called O6-
alkylguanine-DNA alkylatransferase (AGT), removing O-alkyl lesions from DNA 
(Kaina et al., 2007). This is a so-called suicide enzyme as it transfers the alkyl group to 
a cysteine acceptor within itself resulting in its inactivation followed by ubiquitylation 
and degradation (Kaina et al., 2007). Inactivation after alkyl transfer has also been 
reported to facilitate a switch of MGMT from a DNA repair protein to a transcription 
regulator, enabling the cell to sense, as well as respond to, mutagens (Teo et al., 2001). 
The N-alkyl lesions are removed by the oxidative demethylases. There are 9 oxidative 
demetylases in humans. These are homologues of the bacterial AlkB protein, and 
members of a large superfamily of enzymes known as iron (II) and 2-ketoglutarate-
dependent dioxygenases (Aravind and Koonin, 2001; Gerken et al., 2007). They are 
identified based on their homology, but little is know about the AlkB homologue 4 to 9 
(ABH4 to 8 and FTO; fat mass and obesity associated protein). ABH8 has been shown 
to contain an RNA binding motif (Osada et al., 2002), and to be associated with 
generation of intracellular ROS and development of bladder cancer (Shimada et al., 
2009), and FTO is known to remove 3meU and 3meT from ssDNA and RNA (Gerken 
et al., 2007; Jia et al., 2008). FTO was recently identified as an AlkB homologue based 
on sequence similarity, and variants of this protein are associated with obesity in 
humans (Frayling et al., 2007). Besides DNA and RNA repair, the homologues are 
believed to be involved in normal RNA methylation and demethylation, as well as 
demethylation of proteins (Sundheim et al., 2008). 
At this date, most is known about ABH1, 2 and 3. Biochemical studies have shown that 
these homologues can demethylate bases in DNA (ABH1, 2 and 3) and RNA (ABH1 
and 3) by an oxidative demethylation mechanism shown in figure 4 (Duncan et al., 2002; 
Westbye et al., 2008). Similar to the bacterial AlkB, the enzymes use oxygen, 2-
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oxoglutarate (2OG) and iron (Fe2+) to hydroxylate the methylated base (Falnes et al., 
2002; Trewick et al., 2002; Aas et al., 2003). Hydroxymethyl is unstable, and is 
spontaneously released as formaldehyde (Sedgwick, 2004).  
 
 
Figure 4: The general mechanism of the human AlkB homologues. 
Adapted from (Roy and Bhagwat, 2007). 
 
 
The first homologue discovered; ABH1 has the highest sequence similarity to AlkB 
(Aravind and Koonin, 2001; Wei et al., 1996). This homologue is predominantly 
localized in mitochondria where it repairs 3meC in ssDNA as well as in RNA (Westbye 
et al., 2008). ABH3 is localized to the nucleus as well as the cytoplasm and repairs 
1meA and 3meC, preferentially from ssDNA and RNA (Aas et al., 2003). 
The human AlkB homologue studied in this thesis is hABH2, which preferentially 
reverses 1meA and 3meC in nuclear dsDNA (Falnes et al., 2004; Koivisto et al., 2004; 
Aas et al., 2003). Furthermore, hABH2 was recently shown to reverse 1,N6-
ethenoadenine in DNA (Ringvoll et al., 2008). In 2003, our group published that 
hABH2 colocalizes with PCNA in replication foci, suggesting a role for this protein 
close to the replication fork (Aas et al., 2003). Removal of the alkylated lesions by 
hABH2 is therefore believed to act in front of the replication fork, preventing the 
alkylated bases to give rise to mutations. Subsequent studies in knock-out mice showed 
that cells deficient in mABH2 accumulated 1meA in DNA (Ringvoll et al., 2006). 
Embryonic fibroblast cells from these mice were sensitive to MMS, and the removal of 
1meA was impaired, particularly in cells arrested in the S-phase (Ringvoll et al., 2006). 
This supports the importance of hABH2 during replication, suggested by Aas and 
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colleagues (Aas et al., 2003). hABH2 does not, however, contain the PIP-box. When 
searching for the sequence responsible for hABH2’s colocalization with PCNA, we 
found that this sequence, which we called APIM also was responsible for a direct 
interaction between these proteins. The discovery of APIM is described in paper 1.  
Base excision and single strand break repair 
BER is a multistep DNA repair pathway removing damaged bases from DNA. As an 
intermediate in BER, SSBs are formed, and repair of these (SSBR) can be considered to 
be the same pathway as BER after excision of the damaged base. However, SSBs can 
also be formed directly by disintegration of the oxidized sugar from ROS attack, or as a 
result of erroneous or abortive activity of Topo 1 (Caldecott, 2008). The BER/SSBR 
pathway can be both replication coupled and replication independent, described in more 
detail later. SSBs left unrepaired upon replication may be fatal to the cells as they can 
lead to DSBs, demonstrating the importance of replication coupled repair.  
Except for the initial base excision and strand excision steps, BER is essentially the 
same as SSBR illustrated in figure 5. The BER pathway is initiated by DNA 
glycosylases which recognize and cleave the N-glycosylic bond between the sugar 
backbone and the damaged base forming an AP site. There are several DNA 
glycosylases more or less damage specific. Roughly they can be divided into mono- and 
bi-functional glycosylases. The mono-funtional glycosylases simply cut out the 
damaged base, leaving the sugar backbone intact. The bi-functional glycosylases 
however, display an associated lyase function incising 5’ and/or 3’ to the AP site 
(Dalhus et al., 2009).  
SSBs need another detection mechanism to recruit the repair machinery since there are 
no erroneous bases to be recognized. Instead, SSBs are recognized by Poly (ADP-ribose) 
polymerase 1 (PARP1), which rapidly binds and modifies itself and the target proteins 
with chains of PAR (Drew and Plummer, 2009; Hakme et al., 2008). PARP1 is also 
activated by SSBs formed indirectly during BER (Durkacz et al., 1980); however, the 
biological significance of this remains elusive since the damage has arisen during a 
coordinated controlled process where the intermediates are passed on from one enzyme 
 27
to another (Caldecott, 2008). Recent data indicate; however, that PARP1 is needed for 
recruitment of downstream BER/SSBR proteins, particularly the proteins involved in 
the long patch repair described later (Akbari et al., Unpublished). Proteins are recruited 
by the negative charge of the PAR-chain, through interaction by dedicated PARP 
binding motifs (Hakme et al., 2008). 
 
 
 
Figure 5: Sketch of the BER/SSBR pathway after base damage excision 
by the glycosylase. Adapted from (Caldecott, 2008). 
Detection 
End processing 
Gap filling 
Ligation 
Short-patch Long-patch
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After removal of the damaged base by the DNA glycosylase, the AP site formed is 
incised by an AP endonuclease (APE1) 5’ to the AP site creating an SSB. For further 
repair, the ends need to be restored to the conventional 3’-OH and 5’-phosphate. 
Enzymatically, this is the most diverse step in BER (Caldecott, 2008). An example is 
DNA damage from ROS which can leave both phosphate and phosphoglycolate at the 
3’ end. These are processed by polynucleotide kinase 3'-phosphatase (PNK) and APE1 
respectively (Evans et al., 2000; Wiederhold et al., 2004), both binding to the 
scaffolding protein X-ray repair cross-complementing protein 1 (XRCC1) (Caldecott, 
2008; Horton et al., 2008). The gap can be sealed by a single nucleotide (short patch 
BER), or up to 10 nucleotides (long patch BER). Pol β is believed to be the main 
polymerase for gap sealing during BER, at least in short patch BER (Podlutsky et al., 
2001). Pol β is shown to interact with XRCC1 (Caldecott et al., 1994), and to interact 
and colocalize with PCNA and XRCC1 in replication foci (Akbari et al., Unpublished; 
Akbari et al., 2010; Kedar et al., 2002). Notably, Pol β also possesses 
deoxyribosephosphate phosphodiesterase (dRPase) activity (Podlutsky et al., 2001), 
generating a ligatable 5’ end which can be sealed by DNA liagase III (LIG3) which 
forms stable complexes with XRCC1 (Parsons et al., 2005). If the dRP-fragment is 
modified in such a way that it becomes resistant to the dRPase activity of Pol β, the 
dRP-fragment is removed as part of a single strand flap generated by strand 
displacement synthesis in the long patch BER (Akbari et al., 2009; Kubota et al., 1996). 
In long patch BER, Pol β, δ and ε in conjunction with PCNA incorporate nucleotides 
while displacing the old strand generating a flap. This flap is removed by FEN1 and the 
gap is sealed by LIG1 (Pascucci et al., 1999).  
It is still disputed what determines whether BER/SSBR ends up in the short- or the long 
patch pathway.  It has been reported to be dependent on the cell cycle, the presence of 
FEN1, PCNA and PARP1, and the type of damage (Akbari et al., 2009; Caldecott, 2008; 
Fan and Wilson, 2005). Recent studies by our group, however, have shown that after 
DNA insult by low dose of near UVA light, XRCC1 recruits its “core” complex 
containing PNK, Pol β, and likely LIG3 and other short patch BER proteins (Akbari et 
al., Unpublished). Higher dose of the near UVA light; however, recruits PCNA and 
FEN1 which are involved in the long patch BER, indicating that the amount or the 
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nature of the damage determines which path to be activated. Higher accumulation of 
PARP1 at the damaged area by addition of PARP inhibitor recruited long patch proteins 
to micro-irradiated regions also at low UVA doses, suggesting a role for PARP1 in 
signaling long patch BER (Akbari et al., Unpublished). There are several commercially 
available PARP-inhibitors, and inhibition of the PARP1-dependent SSBR has shown 
promising results in the treatment of cancers in patients with defective DSB repair 
(DSBR).  PARP1 has therefore been the subject of extensive research the last few years 
(Bryant et al., 2005; Drew and Plummer, 2009; Helleday et al., 2008).  
In addition to PARP1, the scaffolding protein XRCC1 plays a major role for complex 
formation in BER/SSBR. XRCC1 was first identified due to a mutant in Chinese 
hamster ovary cell (CHO, EM9) (Thompson et al., 1982). The XRCC1 mutant was 
isolated due to its hypersensitivity to  MMS and IR, and the cells displayed defective 
SSBR, increased sister chromatid exchange as well as reduced homologous 
recombination (HR) (Hoy et al., 1987; Thompson et al., 1982). Later, the same group 
cloned the gene, and by expressing the XRCC1 protein in EM9 mutant cells, they found 
that this protein could restore the SSBR to the same level as the XRCC1 wild type 
(CHO AA8) cells (Thompson et al., 1990). The CHO EM9 and AA8 cells are used for 
studies performed for paper 3.  
XRCC1 has no known enzymatic activity, but exerts its effect as a scaffolding protein 
(Caldecott, 2008; Horton et al., 2008). XRCC1 is important for efficient recruitment of 
proteins to BER/SSBR from the early damage recognition in BER by binding to DNA 
glycosylases such as Uracil-DNA glycosylase 2 (UNG2), N-methylpurine DNA 
glycosylase (MPG) also-called 3-alkyladenine DNA glycosylase (AAG), Nei 
endonuclease VIII-like 2 (NEIL2) and 8-oxoguanine DNA glycosylase (OGG1) (Akbari 
et al., 2010; Campalans et al., 2005; Das et al., 2006; Marsin et al., 2003) and by 
binding to PARP1 in SSB recognition (Caldecott, 2008; Horton et al., 2008; Masson et 
al., 1998). Furthermore, XRCC1 is reported to interact with the downstream BER 
proteins Pol β, PNK, PCNA, APE1, LIG3, and PARP1 and 2 (Caldecott, 2008; 
Caldecott et al., 1994; Fan et al., 2004; Masson et al., 1998; Schreiber et al., 2002; Vidal 
et al., 2001). Importantly, XRCC1 binds to itself forming multimers (Akbari et al., 2010; 
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Fan et al., 2004). Also Aprataxin and tyrosyl DNA phosphodiesterase (TDP1) binds to 
XRCC1 (Caldecott, 2008; Plo et al., 2003).  Aprataxin and TDP1 are not essential for 
BER; however, congenital defects in these proteins give rise to neurological disorders 
described later.  
Fully competent short patch and long patch BER complexes can be isolated by 
immunoprecipitation of XRCC1 (Akbari et al., Unpublished; Akbari et al., 2010). There 
seems to be at least three distinct BER/SSBR complexes. One complex is present in 
unthreated cells independent of the cell cycle, one is formed upon DNA insult, and one 
is bound to PCNA at sites of DNA replication (Akbari et al., Unpublished; Akbari et al., 
2010). Results from pull-down followed by BER activity assays by Akbari and 
colleagues lead to suggestion of a model where there are pre-replicative BER/SSBR 
complexes containing UNG2 and XRCC1 proteins and a post-replicative BER/SSBR 
divided into two steps. Post-replicatively, UNG2 is believed to bind PCNA at the site of 
the replication excising the mis-incorporated uracil, forming an AP site which is 
repaired by a tightly followed, but non-interacting, XRCC1 complex (Akbari et al., 
2010).  
XRCC1 consists of tree functional domains, one N-terminal DNA binding domain, one 
internal BRCA1 carboxyl-terminal (BRCT) 1 domain and one C-terminal BRCT2 
domain (Horton et al., 2008). Which domain is important for the scaffolding properties 
of XRCC1 has, however, been somewhat elusive. In paper 3, the relative contribution of 
each of these domains for intra-nuclear localization, recruitment to DNA damage, 
capacity for recruitment of the other BER/SSBR proteins as well as their capacity to 
form functional BER/SSBR complexes are described. The nuclear localization signal 
(NLS) to BRCT1 part of XRCC1 which turned out to be the key region for the function 
of XRCC1, contains three common single-nucleotide polymorphisms (SNPs). These 
SNPs have been the subjects to massive epidemiological studies in the search for 
correlations between the different XRCC1 SNPs and the capacity of DNA repair and 
cancer risk (Vineis et al., 2009). Thus, the repair capacity of XRCC1 with the various 
SNPs was also examined in paper 3. 
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For replication coupled BER/SSBR, PCNA is involved from damage recognition 
through binding of the DNA glycosylases to the final ligation, suggesting a PCNA-
guided ordered reaction (Moldovan et al., 2007). UNG2 is up-regulated during the S-
phase of the cell cycle (Hagen et al., 2008), and colocalizes with PCNA in replication 
foci through its PIP-box (Otterlei et al., 1999). This brings UNG2 to the replication fork 
where it is believed to perform pre- and post-replicative excision of uracil as described 
previously. The glycosylase mutY homologue (MYH) involved in the repair of mis-
incorporated adenine opposite of 8oxoG (Slupska et al., 1996), also interacts with 
PCNA through its PIP-box (Chang and Lu, 2002). MYH is likely involved in post-
replicative removal of mis-incorporated adenine similar to UNG2’s removal of mis-
incorporated uracil (Akbari et al., 2010). In addition, MPG removing methylated purine 
bases, mainly 3meA (O'Connor and Laval, 1991), interacts with PCNA through an 
inverted PIP-box (Xia et al., 2005). 3meA is a replication blocking lesion, thus MPG is 
likely repairing this lesion in a pre-replicative process. PCNA is shown to not only bind, 
but also to stimulate UNG2, NEIL1 and possibly MPG (Dou et al., 2008; Ko and 
Bennett, 2005; Xia et al., 2005). Furthermore, XRCC1, APE1, FEN1, Pol β/ε/δ and 
finally LIG1 interact with PCNA (Dianova et al., 2001; Fan et al., 2004; Moldovan et 
al., 2007). In BER/SSBR independent of replication, PCNA is believed to be mainly 
involved in the long patch gap filling (Caldecott, 2008).  
The involvement of PCNA in BER/SSBR is undisputable, and also PARP1 has been 
reported to interact with PCNA (Simbulan-Rosenthal et al., 1999). PCNA is known to 
be poly (ADP) ribosylated by PARP1, and there seems to be a correlation between S-
phase associated expression of PCNA and PARP1. This suggests a role for PARP1 in 
PCNA expression, possibly by interacting with its promoter (Simbulan-Rosenthal et al., 
1999). Interestingly, conserved APIM motifs are found in PARP1 as well as PARP2 and 
4 (paper 1); however, the biological significance of these motifs in PARP remains to be 
confirmed. 
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Repair of double strand breaks 
DSBs constitute the most serious DNA damage as they can lead to mutations, 
chromosome instability and cell death (Bernstein and Rothstein, 2009). DSBs can be 
formed directly from IR or ROS or indirectly from incomplete BER/SSBR, from 
inhibited Topo II, stalled and collapsed replication fork, low pH and more (Ohnishi et 
al., 2009). To counteract the serious threat of DSBs, cells have evolved two distinct 
pathways, HR and non-homologous end joining (NHEJ). Defects in either one of these 
pathways lead to genetic instability and tumorgenesis (Delacote and Lopez, 2008). HR 
is most efficient when the sister chromatid is close by, thus post replication. NHEJ has 
generally been believed to act during the G1-phase; however, studies have shown that 
NHEJ can act in all stages of the cell cycle (Rothkamm et al., 2003). This enables the 
pathways to complement for each other in all stages of the cell cycle, except in G1 
where there is no template for HR. 
Homologous recombination  
HR is mostly an error-free repair pathway that uses the homology of the sister 
chromatid to direct DNA synthesis across the damaged region. Roughly, Ataxia 
telangiectasia mutated (ATM) and the MRE11/RAD50/NBS1 (MRN) complex mediate 
the cell’s initial response to DSBs. The damaged ends are then modified to generate 
3’ssDNA tails which are substrates for HR. The key proteins RAD51 and RPA bind to 
the 3’ssDNA, forming a nucleoprotein filament. When homology is found, this 
nucleoprotein filament attaches to the sister chromatid invading the double strand, 
forming a so-called D-loop, constituting the template for DNA polymerase (Ohnishi et 
al., 2009). The strand invasion is dependent on RAD51, which is upregulated in many 
cancer types (Richardson, 2005). Another key protein in HR is the BRCA2 protein 
which is the same protein as FANCD1. BRCA2 binds RAD51, thereby restricting its 
action to the sites of DSBs where RAD51 accumulates. BRCA1 is also involved in HR 
repair by binding to the RAD51 and BRCA2; however, the exact mechanism for this 
contribution is not clear (Huen et al., 2010). Other proteins participating in HR are 
RAD51B, RAD51C, RAD51D, XRCC2, XRCC3, RAD54 and RAD54B (Dudas and 
Chovanec, 2004; Ohnishi et al., 2009). The importance of BRCA1 and 2 is visualized 
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by women with BRCA1 and 2 defects. These women are highly predisposed to breast 
and ovarian cancer (Huen et al., 2010; Yu et al., 2000), thus the full name for these 
proteins; breast and ovarian cancer type 1/2 susceptibility protein (BRCA1/BRCA2) 
(Huen et al., 2010). 
PCNA has not so far been reported to directly participate in the HR pathway. However, 
in paper 1, we show that the RAD51 paralog, RAD51B, interacts with PCNA via the 
newly identified APIM motif. RAD51B is thought to assist RAD51 in the early stages 
of HR, and is unique amongst the RAD51 paralogs in that its deficiency results in 
hypersensitivity to DNA damaging agents, chromosomal instability and impaired 
RAD51 foci formation (Date et al., 2006). Furthermore, APIM was also identified in the 
BRCA1/BRCA2-containing complex subunit 45 (pro-BRE) and in the human structural 
maintenance of chromosomes 5 (hSMC5), both involved in HR (paper 1). Interestingly, 
the hSMC5 in complex with hSMC6 has been reported to be necessary for post-
replicative repair of DSBs (Potts et al., 2006). The functionality of APIM in pro-BRE 
and hSMC5, however, remains to be investigated. 
Non‐homologous end joining 
This DNA repair pathway is a straight forward re-ligation of the DNA ends without 
requirement of template, in a manner believed to be error-prone. The fidelity of NHEJ, 
however, depends on the nature of the DSB. DSBs from collapsed replication forks 
mostly generate one-ended DSBs. NHEJ requires two ends, and will ligate the one-
ended DSB with a distal end causing gene rearrangements (Delacote and Lopez, 2008). 
The DSBs formed during G1 such as from IR and ROS leave two proximal ends, 
readily re-ligated by NHEJ (Delacote and Lopez, 2008). Since the main part of the 
genome is non-coding, loss or gain of a few nucleotides may not affect the genetic 
stability.  
Roughly, the Ku70/80 heterodimer binds the DNA ends recruiting and activating DNA-
dependent protein kinase (DNA-PK). DNA-PK phosphorylates the Ku proteins, XRCC4, 
XRCC4-like factor (XLF), Artemis, and itself (Pastwa et al., 2009). Blunt DNA ends 
are ligated by a complex of XLF, XRCC4 and DNA ligase IV (LIG4) (Ahnesorg et al., 
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2006). However, when loss or gain of nucleotides is required, additional nuclease and 
polymerase activities take place. In humans, the endonuclease Artemis and the DNA 
polymerases Pol γ and Pol λ are reported to have roles in formation of blunt ends in the 
NHEJ pathway (Lieber, 2008; Povirk et al., 2007). Interestingly, an alternative DNA-
PK/LIG4/XRCC4- independent pathway has been identified (Audebert et al., 2004). By 
using the DNA strand break chemical Calichemaicin γ1, PARP1 inhibitor, and cells 
proficient and deficient in PARP1, Ku80 and XRCC1, Audbert and colleagues found 
that this alternative pathway requires PARP1 and the ligation activity of XRCC1 - LIG3 
(Audebert et al., 2004). Moreover, the XRCC1 partner PNK is reported to be involved 
in restoration of ligatable ends (Chappell et al., 2002). These are proteins traditionally 
referred to as BER/SSBR proteins, demonstrating the growing evidence of crosstalk 
between the DNA repair pathways.  
As mentioned previously, XRCC1 binds to PCNA (Fan et al., 2004). Moreover, PARP1 
contains the APIM motif described in paper 1 and may also bind to PCNA. Involvement 
of XRCC1 and PARP1 in the alternative NHEJ pathway may therefore recruit PCNA. 
However, so far, there are no reports of PCNA interference with NHEJ, but due to the 
multiplicity of PCNA, a role of PCNA in NHEJ would not be surprising. 
Repair of intrastrand crosslinks  
Intrastrand crosslinking can be formed as a consequence of exogenous insult such as 
UV-B and UV-C and from bifunctional chemical agents commonly used in cancer 
treatment. Furthermore, crosslinks can be formed by endogenous insults such as from 
peroxidized lipids (Friedberg, 2006). The intrastrand crosslinks kink the DNA helix, 
serving as templates for the nucleotide excision repair (NER) pathway. Furthermore, 
specialized DNA polymerases can bypass these intrastrand crosslinks by the so-called 
translesion synthesis (TLS) during replication. 
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Nucleotide excision repair 
NER is the most versatile of the repair pathways as it repairs the diverse group of helix-
distorting DNA lesions, mainly generated by environmental agents (Altieri et al., 2008; 
Hoeijmakers, 2009). These lesions interfere with base pairing, and disrupt transcription 
as well as DNA replication (Kaufmann, 2007; Unsal-Kacmaz et al., 2007). Even so, this 
pathway has not yet been reported to be coupled to replication. The lesions repaired by 
NER include pyrimidine dimers (mainly (6-4) photoproducts) caused by UV radiation 
(figure 3) and “bulky” chemical adducts that are incorporated in the DNA disrupting the 
folding (Nouspikel, 2009). Dependent on whether the damage occurs in the actively 
transcribed domains or elsewhere in the genome, repair is initiated by either of the two 
sub pathways; transcription coupled nucleotide excision repair (TCR), dealing with 
damage blocking the RNA polymerase or global genome nucleotide excision repair 
(GGR) recognizing damage throughout the genome (Nouspikel, 2009). Figure 6 shows 
a simplified sketch of TCR and GGR. 
In TCR, the stalled RNA polymerase complex recruits Cockayne syndrome A and B 
(CSA and CSB) proteins. CSA has been shown to polyubiquitylate CSB, causing its 
release and degradation (Groisman et al., 2006). In GGR, recognition of the DNA 
damage is dependent on the kink. In the cases where the DNA lesions are causing a 
strong kink, e.g. (6-4) photoproducts, Xeroderma pigmentosum (XP) group C in 
complex with human homologue of yeast Rad23 protein (HR23B) recognize the lesion 
(Nouspikel, 2009; Sugasawa et al., 1998). DNA lesions causing a more modest kink, e.g. 
CPDs; however, are first recognized by damage DNA binding protein 1 (DDB1) 
together with an XPE/DDB2 complex. This heterodimer increases the kink, making it 
readily recognizable for the XPC complex (Chu and Chang, 1988; Nouspikel, 2009; 
Tang and Chu, 2002). After damage recognition, GGR and TCR are identical. The ten-
component basal transcription factor II H (TFIIH) interacts with XPC from GGR or the 
stalled transcription apparatus from TCR. XPB and XPD, components of TFIIH are 
DNA helicases unwinding the DNA (Evans et al., 1997; Sarker et al., 2005). This makes 
space for binding of XPA and RPA, preventing reannealing (Evans et al., 1997). The 
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strand is cleaved by ERCC1-XPF and XPG, and the damaged oligonucleotide (25-30 
bases) is removed (Mu et al., 1996; O'Donovan et al., 1994). Finally, the remaining gap 
is filled by the DNA replication machinery (Popanda and Thielmann, 1992; Shivji et al., 
1992) and sealed by DNA ligase, presumably by LIG3 in complex with XRCC1 (Moser 
et al., 2007; Ogi et al., 2010).  
 
 
Figure 6. Simplified sketch of NER, from damage recognition to 
incision (Cleaver 2009). 
 
All together, more than 30 proteins participate in the NER pathway (Hoeijmakers, 
2009). XPA has an essential, but not yet fully understood role in the core incision 
complex, where it is believed to be involved in damage verification and tethering of 
DNA and the other NER subunits (Camenisch and Nageli, 2008; Nouspikel, 2009). 
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Furthermore, a recent publication suggests a presence of XPA in the process all the way 
from damage verification to the repair synthesis (Luijsterburg et al., 2010). Despite the 
small size (273 amino acids), XPA has many binding partners. XPA is reported to 
interact with RPA, XPC-HR23B, TFIIH, ERCC1, XPC, and XPA-binding protein 1 and 
2 (XAB1 and XAB2) (Camenisch and Nageli, 2008; He et al., 1995; Krasikova et al., 
2008; Matsuda et al., 1995; Nakatsu et al., 2000; Nitta et al., 2000; Tsodikov et al., 2007; 
You et al., 2003). Finally, XPA is reported to interact with DNA (Kuraoka et al., 1996), 
and itself forming dimers (Yang et al., 2002). Unlike the other NER proteins, XPA has 
no other known biochemical functions, thus impairing XPA will specifically affect NER. 
This makes XPA a potential target for improving cancer chemotherapy, and certain 
studies have shown that by impairing XPA directly, cells are sensitized to the 
crosslinking agent cisplatin (Cummings et al., 2006; Wu et al., 2003). 
The presence of PCNA is indispensable for functional NER (Moldovan et al., 2007; 
Shivji et al., 1992). In 1997 PCNA was shown to participate in the DNA repair 
synthesis step in NER, through binding to the N-terminal of XPG. They also showed 
that this domain was essential for PCNA binding and NER activity (Gary et al., 1997). 
Subsequent studies showed that this N-terminal PCNA binding domain in XPG was the 
conserved PIP-box motif (Warbrick, 2000). Moreover, in paper 2, we show that also the 
scaffolding NER protein XPA binds to PCNA mediated by the APIM motif, and that 
this interaction is required for proper function of the NER pathway. 
Lesion bypass  
Arrested replication fork is a challenge for the cell, and prolonged stalling can result in 
fatal DSBs. Conserved from bacteria to humans, cells possesses mechanisms for 
replicating past certain types of lesions, by using specialized TLS DNA polymerases. In 
humans, there are currently 9 known specialized polymerases, termed Pol η (eta),  ι 
(iota), κ (kappa), λ (lambda), μ (mu), θ (theta), ζ (zeta, Rev3), Rev1, and ν (nu) (Loeb 
and Monnat, 2008). These polymerases can temporarily switch with the blocked 
replicative DNA polymerases and polymerize over the damaged DNA. This is possible 
because these TLS polymerases have more flexible base-pairing properties enabling 
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them to bypass the lesions. The flexibility, however, makes them “sloppy” and not as 
accurate as the replicative DNA polymerases. Moreover, unlike the replicative 
polymerases (Pol δ,ε,γ) the TLS polymerases lack proofreading activity. Together with 
the flexibility, this contributes to a common reference of these polymerases as error-
prone, thereby mutagenic (Loeb and Monnat, 2008; Wang, 2001). Some polymerases 
have distinct biological roles, and Pol η replicates accurately past T-T CPDs from UV 
irradiation. In the absence of Pol η, the TLS polymerases Pol ι, Pol κ, Pol ζ, and Rev1 
may bypass CPDs, however, in an error-prone manner. Thus, cells lacking Pol η are 
hypermutable following UV exposure, visualized by the skin cancer predisposition 
syndrome XP variant (XPV) (Huang and D'Andrea, 2006; Inui et al., 2008; Pfeifer et al., 
2005; Vaisman et al., 2003). Also, Pol , Pol , and Rev1 can copy past bulky DNA 
adducts, while Pol ζ and Pol θ are believed to be important for bypass of DNA 
crosslinks (Loeb and Monnat, 2008). Furthermore, Pol η, Pol ζ, Pol μ, and possibly Pol ι, 
may also participate in somatic hypermutation involved in antibody maturation (Wang, 
2001; Zhu and Zhang, 2003).  
Switching from the replicative DNA polymerase and deciding which of the TLS DNA 
polymerases to use, is probably to a large extent determined by PTMs on PCNA. 
Ubiquitylation of PCNA is one of the best characterized examples of how PTMs on 
PCNA regulate its action (Lee and Myung, 2008; Moldovan et al., 2007). 
Monoubiquitylation on PCNA at K164 is reported to increase the affinity towards the 
TLS polymerases (Huang and D'Andrea, 2006). The ubiquitin dependent binding of the 
TLS polymerases to PCNA is widely believed to be physically coupled to stalled 
replication forks (Davies et al., 2008; Ulrich, 2009; Yang and Zou, 2009). This has 
recently been challenged by Karras and Jentsch. They suggest that TLS triggered by 
monoubiquitylation of PCNA not normally mediates bypass at stalled replication forks, 
but rather mediates bypass post replication or even outside of the S-phase, at least in 
yeast (Karras and Jentsch, 2010). Pol η, Pol ι and Pol κ all bind PCNA through their 
PIP-boxes (Moldovan et al., 2007). Pol ζ on the other hand, contains the newly 
discovered APIM motif (paper 1), however, whether this motif is functional in Pol ζ, 
remains to be determined. 
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Repair of interstrand crosslinks 
Most crosslinking agents generate both intrastrand crosslinks and ICLs, however, the 
ICLs are believed to be more severe as they pose a complete block of both transcription 
and DNA replication (McCabe et al., 2009). The repair of ICL is complex and not yet 
fully understood, however, it is believed to be both replication dependent, relying on the 
FA, HR and NER pathways and replication independent, relying on NER and TLS 
(Karras and Jentsch, 2010; Wang, 2007; Wang et al., 2001).  
The Fanconi anemia pathway 
The FA pathway was identified due to the rare cancer predisposition syndrome with the 
same name caused by mutation in any of the 13 hitherto known FANC genes. Little is 
known about the mechanism of the FA pathway, but it is known to be crucial for 
replication-coupled repair of ICLs. The FA proteins form complexes with each other as 
well as with proteins from the HR pathway (Bagby and Alter, 2006; Knipscheer et al., 
2009). The FA pathway is believed to act in front of the replication fork, where it is 
somehow involved in the repair of ICLs, enabling the replication fork to progress 
(Wang, 2007).  The 13 FANC proteins can be divided into three groups based on their 
function. Group I consists of 8 FA proteins constituting the core complex (FANCA, B, 
C, E, F, G, L, and M). Group II consists of FANCD2 and I, both of which are 
ubiquitylated by FA group I proteins and proposed to bind to DNA (Knipscheer et al., 
2009; Wang, 2007). Group III consists of FANCD1 (BRCA2), J and N and are 
connected to breast cancer (Wang, 2007). Homozygous mutations in any of the FANC 
genes cause the FA disorder, while heterozygous mutations in any of the group III 
FANC genes predispose female carriers to breast cancer (Knipscheer et al., 2009; Wang, 
2007). Some of the FA proteins have enzymatic activities: FANCM (group I) contains 
domains for helicase and endonuclease activities and has translocase activity; FANCJ 
(group III) is a DNA helicase interacting with BRCA1; and finally FANCD1 (BRCA2) 
(group III) is a regulator of RAD51.  
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Even though the FA pathway is replication dependent, an involvement of PCNA has not 
yet been demonstrated (McCabe et al., 2009; Wang, 2007). In paper 1, however, we 
report that one of the core FA proteins, FANCC (group I), contains the APIM motif. 
The functionality of APIM in FANCC, however, remains to be determined. 
 
  
Figure 7. One of the models proposed to describe replication coupled 
repair of ICLs. A: Replication fork arrest at ICL recruits and activates the 
core FA proteins (group I). Group I FA ubiquitylates group II FA proteins. 
B: Unhooking of the crosslink by XPF-ERCC1 and MUS81-EME1. C: FA 
group III facilitates clearing of DNA and loading of TLS polymerases, 
creating a DSB. D-E: NER removes the remaining adducts and repairs the 
gap. F: FA group II recruits BRCA1-RAD51, promoting HR. G: 
Resolution of the recombination by FA helicases, and replication fork 
restart. Adapted from (Wang, 2007). 
 
There are several theories for how repair of replication associated ICLs takes place. One 
model proposed by Wang is shown in figure 7 (Wang, 2007). The damage recognition 
is believed to be initiated by either collapsed replication fork or the FA proteins 
(McCabe et al., 2009). Recognition is tightly followed by incision near the ICL 
involving the NER heterodimer ERCC1/XPF and MUS81/EME1 unhooking the ICL 
A B C 
D E 
F G 
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(7B). The remaining gap may be resynthesized by TLS forming a DSB (7C) (Nojima et 
al., 2005; Wang, 2007). The FA group III protein FANCJ helicase is believed to 
facilitate clearing of DNA and loading of the TLS polymerase (Wang, 2007). The 
remaining DSB is further repaired by the HR pathway shown to be essential for error-
free repair of ICLs, where RAD51 plays an important role (7F) (Godthelp et al., 2002; 
Nojima et al., 2005). Finally, the FA helicases (FANCJ and M) are believed to resolve 
the recombination enabling restart of the replication fork (Wang, 2007).  
To complicate the story further, the previously mentioned replication coupled MMR is 
also involved in ICL repair. Upon treatment with crosslinking anti-cancer drugs such as 
cisplatin, MMR is reported to signal cell cycle arrest due to the so-called futile cycle, 
eventually leading to strand break and cell death (Jiricny, 2006; Meyers et al., 2003). 
Thus, the MMR pathway induces cell death in response to cisplatin treatment, and 
deficient MMR is related to increased resistance to cisplatin (Jiricny, 2006; Meyers et 
al., 2003; Wang and Lippard, 2005). Interestingly, the NER complexes XPA - RPA and 
XPC - HR23B have been reported to cooperate with the MMR complex MutSβ in 
recognition of ICLs (Thoma et al., 2005; Zhao et al., 2009).  
An HR-independent repair of ICL, probably also independent of replication, exists. This 
repair involves TLS together with the NER pathway and is unlike replication-dependent 
repair of ICL, error-prone (Wang et al., 2001). NER is believed to incise on both sides 
of the lesion, followed by TLS and another action of the NER pathway, resulting in 
removal of the ICL (McCabe et al., 2009; Wang et al., 2001). In this case, TLS is 
predominantly carried out by Pol ζ, at least in mouse and avian cells (Shen et al., 2006). 
Pol ζ is dependent on PTM modified (monoubiquitylated) PCNA and Rev1 for bypass 
of ICLs, in a process recently suggested to be independent of replication (Karras and 
Jentsch, 2010; Shen et al., 2006). A direct interaction between Pol ζ and PCNA has, 
however, not been demonstrated (Shen et al., 2006). Notably, Pol ζ contains the APIM 
motif described in paper 1. The PCNA form binding to the APIM containing proteins 
also has a PTM modification; however, the nature of this PTM is not yet known. 
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Clinical  features  of  patients  with  hereditary  defects  in 
DNA repair pathways  
The importance of the particular DNA repair pathways are demonstrated by the severe 
consequence for people with congenital DNA repair impairments, leading to 
predisposition to cancer or other diseases.  
Perhaps the most pronounced disorder comes from defects in the NER pathway, with 
three rare human disorders, Xeroderma pigmentosum (XP), Cocayne syndrome (CS) 
and trichothiodystrophy (TTD). The skin cancer disease XP arises from mutations in 
one of the seven XP genes. The XP patients exhibit a >1000-fold increase in the 
incidence of sun-induced skin cancer, and 20% of the patients also develop neurological 
abnormalities dependent on which gene is defective (Cleaver et al., 2009; Hakem, 2008; 
Hoeijmakers, 2001). XP patients with defects in the GGR damage recognition proteins 
XPC and XPE have the lowest level of neurological damage, probably because RNA 
polymerase II is unaffected (Cleaver et al., 2009). CS is a rare human autosomal 
recessive inherited genetic disease. CS patients have growth retardation, progressive 
cognitive impairment and they die young. Similar to the XP patients they are also 
excessively sun sensitive, but do not seem to be predisposed to skin cancer. The CS 
disorder is caused by mutations in CSA or CSB genes, and CS cells therefore fail to 
recover gene transcription after DNA damage. Arrested RNA polymerase will induce 
apoptosis, thus damaged cells are lost rather than mutated. This explains why CS is not 
associated with increased cancer risk (Cleaver et al., 2009; Thoms et al., 2007). TTD is 
also a rare human autosomal recessive disorder caused by defective NER. In this case, 
the mutations are found in the XPB or XPD helicase genes. The TTD patients suffer 
from brittle hair and nails, dwarfism and ataxia, and half of the patients are sensitive to 
sunlight, however, as for CS patients, TTD patients do not seem to be predisposed to 
skin cancer (Cleaver et al., 2009; Thoms et al., 2007). 
Sun sensitivity is also observed in patients with mutations in the TLS polymerase Pol η 
demonstrating its role in UV damage bypass (Pfeifer et al., 2005; Stary and Sarasin, 
2002). These patients have normal NER function, and the disorder was therefore named 
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XPV prior to the identification of Pol η in 1999 (Masutani et al., 1999). The XPV 
patients are not as sensitive to UV light as the NER deficient XP patients; however, they 
are significantly predisposed to various types of skin cancers as a response to UV light 
from the sun (Inui et al., 2008).  
Defects in the MMR pathway are related to development of hereditary non-polyposis 
colon cancer (HNPCC). Mutations in the MSH2 or MLH1 genes are most common 
(Hakem, 2008), but such mutations only constitute 3-4 % of all colorectal cancer 
incidents (Hsieh and Yamane, 2008). Defects in SSBR also lead to rare genetic 
disorders; Ataxia-oculomotor apraxia 1 (AOA1) and the even more seldom disorder; 
Spinocerebellar ataxia with axonal neuropathy 1 (SCAN1). None of the disorders result 
in genetic instability; instead they are characterized by ataxia and other neurological 
defects (Caldecott, 2008). The AOA1 disorder originates from mutations in the gene 
encoding aprataxin and SCAN1 from mutations in the gene encoding TDP1, both 
binding partners of the scaffolding proteins XRCC1 (Caldecott, 2008; Plo et al., 2003). 
Defects in BRCA1 and BRCA2 proteins predispose women to breast and ovarian cancer. 
As described previously, these proteins are important for HR repair of the fatal DSBs. 
BRCA1 is furthermore important for cell cycle regulation by interacting with numerous 
cell cycle checkpoint and repair proteins through its BRCT domain. Moreover, BRCA1 
is involved in DNA replication by regulating the ubiquitylation status of Topo II α 
(Huen et al., 2010). Pernicious homozygous mutations in any of the two BRCA genes 
result in enhanced chromosomal alterations termed gross chromosomal rearrangements 
which are the leading cause of cancerous mutations (Yu et al., 2000). For breast cancer, 
only 5 to 10% of the women carry mutation in BRCA1 or BRCA2. However, a woman 
carrying BRCA1 or BRCA2 mutations in one allele, has 40 to 80% chance of developing 
breast cancer, making these mutations the strongest breast cancer predictors know 
(Fackenthal and Olopade, 2007).  
Furthermore, homozygous mutations in any of the 13 FANC genes result in the genetic 
cancer predisposition syndrome FA. Genetically, the disease is characterized by 
chromosomal instability and hypersensitivity to ICLs (Wang, 2007). The phenotype is 
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characterized by bone marrow failure and high risk of myelodysplasia, acute 
nonlymphocytic leukemia and certain epithelial malignancies. In addition, the patients 
usually have particular features such as growth retardation, small head size, and café-au-
lait spots; however, some patients acquire the characteristic features in adulthood 
(Bagby and Alter, 2006). As discussed for ICL repair, the FA pathway seems to work in 
tight collaboration with HR, however, the FA patients does not seem to be predisposed 
to breast or ovarian cancer. Heterozygous mutation in the group III FANC genes 
(FANCJ and FANCN in addition to FANCD1/BRCA2), however, seems to predispose 
women to breast cancer (Wang, 2007). 
DNA repair and cancer therapy 
The overall goal of cancer chemotherapeutic treatment is to impose a huge enough 
threat to the cells’ DNA to make the cells give up and die. Our natural defense against 
these threats, DNA repair, will counteract these insults, and will ironically impair the 
cancer treatment. One approach for improving cancer treatment is therefore to modulate 
the DNA repair to increase the drug efficacy. Another approach is to take advantage of 
the cancer cells’ defective DNA repair pathways, such as in the case of the BRCA1 and 
2 deficient breast and ovarian cancers, which have reduced ability to repair DSBs. 
However, each cancer is genotypically different, thus personalized medicine has a 
potential for utilizing the particular genetic features for each of the cancer incidents. 
Alkylating agents are widely used in cancer treatment (table 1). The direct repair protein 
MGMT is important for repair of O-alkylated lesions; however, the enzyme is 
inactivated and degraded after repair (Kaina et al., 2007). Thus, pseudo substrates for 
MGMT can be used in combination with temozolomide (which causes O6meG). This 
will decrease the amount of active MGMT, and increase the effect of temozolomide. A 
class of pseudo substrates for MGMT is currently being tested in clinical trials in 
combination with temozolomide (Sharma et al., 2009). 
At this date, the hottest DNA repair protein target for cancer therapy is PARP. Most is 
known about PARP1, which is involved in several DNA repair pathways, but most 
 45
importantly in BER/SSBR. Inhibition of PARP1 will impair SSBR, leading to the 
formation of DSBs. The use of PARP inhibitor has been suggested to work as a 
combination therapy for several types of cancers (Helleday et al., 2008); however, the 
indisputably best effects of PARP inhibitors is seen in BRCA1 and BRCA2 deficient 
cancer cells. Women with inherited heterozygous BRCA1 and BRCA2 defects have one 
functional allele; however, the cells that have developed into tumor cells have lost the 
functionality of both alleles (Yu et al., 2000). Consequently, the cancer cells in these 
patients display impaired DSBR by the HR pathway (Bryant et al., 2005; Farmer et al., 
2005). By threating cells with PARP inhibitors, the SSBR is impaired, leading to 
accumulation of SSBs. SSBs left unrepaired form fatal DSBs. During DNA replication 
in normal repair proficient cells, these DSBs are repaired by HR. However, in the HR 
impaired BRCA1 and BRCA2 deficient cancer cells, more DSBs will remain unrepaired, 
leading to collapse of the replication fork and subsequent cell death (Bryant et al., 2005; 
Farmer et al., 2005). The use of PARP inhibitors is in phase III clinical trials and show 
promising results for these patients (Rouleau et al., 2010).  
As our knowledge about the whole DNA repair machinery grows - which proteins are 
involved in repair of the various DNA lesions, how the proteins are modified and how 
they work together in complexes to efficiently repair the DNA - new possibilities for 
modulation of DNA repair emerge. Overexpression of an APIM containing fusion 
protein sensitized cells to various DNA damaging agents, including several anti-cancer 
drugs (paper 1 and 2). Thus, the APIM-peptide may be a potential DNA repair 
modulator for future cancer treatment. The intense basic research on DNA repair the last 
few decades will likely identify several new ways to modulate DNA repair, providing 
us with better and more customized cancer medicine in the future. 
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AIMS OF THE STUDY 
The overall goal of this thesis was to study protein interactions in DNA repair using 
sophisticated in vivo cell biology based experiments. Use of confocal microscopy 
enables the study of fluorescently tagged proteins in living cells, in an environment 
close to reality. Our aim was to identify the regions within the particular DNA repair 
proteins responsible for complex formation with other DNA repair proteins and the 
“Maestro of the replication fork”, PCNA. Furthermore, we wanted to investigate the 
biological significance of these interactions in terms of repair efficiency and cell 
survival. 
In 2003, our group published that hABH2 colocalizes with PCNA in replication foci 
(Aas et al., 2003); however, unlike many other known proteins colocalizing with PCNA, 
it did not contain the PIP-box. The first aim of this thesis was therefore to reveal 
whether hABH2 and PCNA were directly interacting, and to find the region of hABH2 
responsible for its complex formation with PCNA. The search for the PCNA interacting 
region in hABH2 turned into an identification of five conserved amino acids 
constituting a novel PCNA interacting motif, which we termed APIM. This motif was 
found in more than 200 proteins, many with distinct roles in DNA repair. Whether 
APIM was a functional motif in these proteins, however, was not known. Thus, the next 
aim was therefore to investigate the functionality of APIM in XPA, with an essential but 
not yet fully understood role in NER.   
Numerous papers dealing with XRCC1 and its binding partners have been published. 
XRCC1 contains three conserved domains, reported to bind various repair proteins in 
vitro. However, which of these domains that is responsible for its localization to 
replication and to damaged areas, as well as its ability to recruit its binding partners, has 
been somewhat elusive. Furthermore, several SNPs within XRCC1 are associated with 
cancer. Therefore, the final and slightly different aim of this thesis was to study the 
ability of the various XRCC1 deletion mutants and SNP variants for intra nuclear 
migration, complex formation, protein recruitment, and repair capacity. 
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PAPER SUMMARY 
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Identification of a novel, widespread, and functionally important PCNA‐
binding motif 
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Hans E. Krokan, and  Marit Otterlei 
† These authors contributed equally to this work 
 
hABH2 colocalizes with PCNA in replication foci (Aas et al., 2003), but lacks the 
PCNA interacting peptide (PIP) box found in many proteins colocalizing with PCNA 
(Warbrick, 2000). Thus, the work for this paper started with dissecting hABH2, finding 
the smallest possible part responsible for its colocalization with PCNA, and 
examination of whether this sequence also mediated direct binding to PCNA. 
By fluorescently tagged overexpressed proteins, confocal imaging, dot blot and pull-
down assays we found that 5 conserved amino acids in the N-terminal of hABH2 were 
responsible for the colocalization between hABH2 and PCNA. Dot blot and subsequent 
in vivo confocal imaging showed that a conserved aromatic amino acid in position 2 (F, 
Y or W) of the 5 amino acid motif was crucial for its binding to PCNA. Positive 
fluorescence resonance energy transfer (FRET) indicates that the proteins are within 10 
nm, and pull-down of crosslinked proteins indicates that the proteins are within 0.2 nm 
of one another (Matyus, 1992; Vasilescu et al., 2004). By using these two approaches, 
we found it most likely that the interaction between hABH2 and PCNA was direct. We 
termed this 5 amino acid motif AlkB homologue 2 PCNA interacting motif (APIM). 
Results from the fractionated pull-down assays suggested that only a part of the 
available hABH2 and PCNA - predominantly in the chromatin enriched fraction, 
interacted. This may indicate that PCNA, hABH2, or both need to be PTM modified to 
interact. This was supported by 2 dimensional gel electrophoresis analyses which 
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showed that APIM pulled down a modified form of PCNA; however, the nature of this 
modification is still enigmatic.  
The functionality of APIM in hABH2 was illustrated by mutating F in position 4 in 
hABH2 to A, which totally disrupted colocalization with PCNA. Moreover, 
overexpression of APIM-YFP in S-phase cells threated with MMS lead to an elevated 
level of 3meA, and increased the sensitivity to MMS, measured by colony forming and 
MTT assays. However, APIM also sensitized cells to other DNA alkylating agents 
(Carmustine/BCNU, Mitomycin C and Temozolomide) introducing DNA damage not 
believed to be repaired by hABH2.  
Using the APIM motif (K/R)-(F/Y/W)-(L/I/V/A)-(L/I/V/A)-(K/R) as a query, we 
obtained hundreds of hits in the Swiss-Prot/TreEMBL database. Of these, about 200 
proteins had conserved APIM and were believed to be localized in the nucleus. Many of 
these proteins are involved in cellular stress-responses to DNA damage. Of the APIM 
containing proteins found, we verified functional APIM sequences in four proteins in 
addition to hABH2: transcription factor II S Like; transcription factor II-I; DNA 
topoisomerase II α; and RAD51B. All proteins colocalized and gave positive FRET 
with PCNA in replication foci. Importantly, mutation of the conserved amino acid (F to 
A) in APIM sequence in all these proteins either abolished colocalization or reduced 
FRET with PCNA, demonstrating the functionality of APIM in these proteins. In fact, 
the general transcription factor TFII-I has four APIM motifs. Mutation of either one of 
these motifs reduced FRET, and mutation of all four together totally abolished 
colocalization with PCNA. This suggests that several motifs can compete for stronger 
binding to PCNA.  
To summarize, this paper presents the finding of a new PCNA interacting motif, called 
APIM, first discovered in hABH2. This motif binds directly to a modified form of 
PCNA in replication foci. A conserved APIM is found in more than 200 nuclear 
proteins, and a functional motif is demonstrated for 4 of these in addition to hABH2. 
Overexpression of this motif sensitizes cells to various DNA damaging agents 
introducing various types of lesions in DNA. 
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Paper 2, Manuscript submitted May 2010:  
Proper functioning of the Xeroderma Pigmentosum group A protein is 
dependent on interaction with PCNA  
Karin M. Gilljam, Rebekka Müller, and Marit Otterlei 
 
The identified PCNA interacting motif, APIM (paper 1), was found in more than 200 
proteins; however, the functionality of APIM in these proteins is not known. This paper 
investigated the functionality of APIM in the core NER pathway protein Xeroderma 
pigmentosum group A (XPA). 
Experimentally, we made use of fluorescently tagged overexpressed proteins, confocal 
imaging, FRET, dot blot, pull-down, siRNA knock down, and MTT assay to examine 
the functionality of APIM in XPA. We found that XPA colocalized with PCNA in 
replication foci, and that XPA and PCNA were co-immunoprecipitated. Similar to what 
we found for the hABH2 - PCNA interaction (paper 1), the XPA - PCNA interaction 
seemed to be stronger in the chromatin enriched fraction than in the soluble fraction, 
probably requiring the PTM form of PCNA found in paper 1. Furthermore, FRET 
analysis indicated that XPA and PCNA were in close proximity. The APIM motif found 
in XPA is conserved within the DNA binding part of XPA, and these 5 conserved 
amino acids from XPA were sufficient for a close interaction with PCNA both in vitro 
(dot blot) and in vivo (confocal imaging including FRET measurements).  
Unlike hABH2, transcription factor II S Like, transcription factor II-I, DNA 
topoisomerase II α, and RAD51B in paper 1, mutation of APIM in XPA did not reduce 
colocalization nor FRET with PCNA in HeLa cells. However, XPA has been reported to 
form dimers (Yang et al., 2002), and our FRET measurements supported this. Therefore, 
we used XP-A deficient fibroblast cells (GMO4429) for colocalization and FRET 
analysis. We found a strong reduction in FRET between XPA mutated in APIM and 
PCNA compared to the wild type constructs. However, the mutant XPA still colocalized 
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with PCNA, probably through its other binding partners. Notably, one of its binding 
partners, named XPA binding protein 2 (XAB2) also contains APIM (paper 1). 
We found that overexpression of an APIM-peptide severely increased the sensitivity for 
damage from UV-B irradiation, which primarily is repaired by the NER pathway 
(Nouspikel, 2009). Importantly, by using siRNA knock down of XPA, we showed that 
the increased sensitivity against UV-B in cells overexpressing APIM compared to 
control cells was dependent on the presence of XPA. This strongly suggests that the 
UV-B sensitizing effect of APIM overexpression was due to reduced NER imputable to 
impaired binding between XPA and PCNA.  
To summarize, this paper shows that XPA colocalizes and binds directly to PCNA 
through the newly discovered APIM motif, and that overexpression of APIM sensitized 
cells to UV-B only when XPA is present.  
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Paper 3, manuscript:  
The NLS to BRCT1 region of XRCC1, harbouring the three most common 
single nucleotide variations, is essential for the scaffolding function of 
XRCC1. 
 
Audun Hanssen‐Bauer†, Karin Solvang‐Garten†, Karin M. Gilljam, Kathrin Thorseth, 
David M. Wilson III, Mansour Akbari, and Marit Otterlei  
† These authors contributed equally to this work 
 
The scaffolding protein XRCC1 is composed of several conserved domains, all 
involved in interactions with different proteins. However, which of these domains is 
important for the scaffolding function, and the ability of XRCC1 to be recruited to sites 
of DNA damage or DNA replication, is somewhat elusive. Furthermore, SNP variants 
of XRCC1 have been associated with increased cancer incidents. Thus, in this paper we 
examined three different deletion mutants and three different SNP variants of XRCC1 
and compared them with the full length, conservative protein in an XRCC1-/- 
background.  
To investigate which part of XRCC1 was required for recruitment to sites of DNA 
damage, we used fluorescently tagged deletion mutants of XRCC1 (N-terminal, internal 
and C-terminal mutant). By introducing local damage by near UVA laser (405nm) 
during confocal imaging, we found that the BRCT1 region (present in both the internal 
and the C-terminal mutants) was essential for migration to sites of DNA damage. By co-
expressing the XRCC1 deletion mutants with PCNA, PNK and Pol β, we found that the 
mutants carrying the suggested binding sites from in vitro experiments (Fan et al., 2004; 
Whitehouse et al., 2001), in addition to the BRCT1 domain, increased the recruitment of 
these proteins to micro-irradiated regions. Furthermore, we found that the BRCT1 
region was absolutely required for colocalization of XRCC1 with sites of DNA 
replication, and that this colocalization was independent of the XRCC1-PCNA 
interaction sites.  
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Comet assay analysis, measuring single and double strand breaks as well as alkali labile 
sites, revealed that only the internal deletion mutant containing the region from NLS 
through BRCT1 had the capability to partly complement XRCC1 in XRCC1-/- cells after 
MMS challenge. This mutant neither binds Pol β nor LIG3, but contains the reported 
binding site for the 3-methyl-adenine DNA glycosylase (MPG) (Campalans et al., 2005), 
important for repair of methylated bases from MMS exposure. Thus, this mutant had the 
ability to colocalize with PCNA and MPG - two properties likely important for the 
complementation of XRCC1 for alkylation repair. The complementation observed 
despite the lack of Pol β and LIG3 binding sites may indicate that the repair of alkylated 
bases by MPG is most important during replication when other polymerases and DNA 
ligase I from the replication machinery are available. The internal mutant also possesses 
the binding site for OGG1, NEIL2 and NTH1 repairing oxidative base damage 
(Campalans et al., 2005; Marsin et al., 2003), however, this mutant could not 
complement for XRCC1 after H2O2 challenge.  
The three common SNPs in XRCC1, Arg194Trp, Arg280His and Arg399Gln have been 
associated with increased incidence of specific cancers. All these SNPs are found within 
the important NLS - BRCT1 region of XRCC1. When comparing these SNP variants of 
XRCC1 with the conservative protein in our cell biology based experiments, we could 
not detect significant differences with regard to intra-nuclear localization or their ability 
to recruit Pol β or PNK to micro-irradiated regions. However, we found a slightly 
reduced ability to form and to maintain foci upon micro-irradiation as well as a slightly 
different repair profile after MMS and H2O2 treatment in two of these SNP variants 
compared with the conservative XRCC1. Small variations in repair profiles could have 
significant implications in vivo. 
To summarize, the BRCT1 domain of XRCC1 is important for its accumulation to local 
DNA damage, and the mutants carrying the suggested binding sites for PCNA and PNK 
recruited these proteins to the micro-irradiated regions. The internal NLS - BRCT1 
domain was further required for partial complementation of XRCC1 for alkylation 
damage repair. This part of XRCC1 carries three known SNPs showing slightly 
different accumulation upon micro-irradiation and in vivo repair efficiency.  
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DISCUSSION OF RESULTS AND PLANS FOR THE FUTURE 
To increase the efficiency of DNA repair, proteins cluster together to be at the right 
place at the right time. Efficient DNA repair is vital during DNA replication, and the 
replication associated repair complexes - often mediated through binding to PCNA - has 
been our main focus.  
Complex  formation with PCNA  increases  the DNA  repair efficiency and 
cell survival 
Direct repair of alkylation damage by hABH2 has previously been reported to be 
localized to the replication fork (Aas et al., 2003), and to be required for efficient repair 
of 1meA during replication (Ringvoll et al., 2006). In paper 1, we showed that the 
interaction between hABH2 and PCNA is direct, mediated by a five amino acid motif 
which we termed APIM. Overexpression of this motif sensitized cells to damage from 
MMS, and increased the amount of 1meA in MMS threated HeLa cells arrested in S-
phase. The sensitization by APIM is probably caused by blockage of the binding site for 
hABH2 on PCNA as illustrated in figure 8. This strongly indicates that hABH2 works 
more optimal while it is in complex with PCNA. We believe that hABH2 is bound to 
PCNA that is present close to the front of the replication fork during steady state 
replication of the genome. Alternatively, it may be in the vicinity of the replication fork 
and bind to PCNA with high affinity when the replication is stalled, similar to what is 
suggested for the TLS polymerases (Kannouche et al., 2004). 
The core NER protein XPA has many binding partners, but the endonuclease XPG has 
been the only NER protein reported to bind to PCNA (Camenisch and Nageli, 2008; 
Gary et al., 1997). However, a recent publication investigating the assembly and 
disassembly of the NER proteins after UV-irradiation showed that XPA, not XPG, 
remained present in the final repair synthesis step, only accompanied by PCNA and 
RPA (Luijsterburg et al., 2010). They also suggested that XPA binds to the repair 
synthesis intermediate with high affinity. In accordance with this, we suggested that 
XPA binds directly to PCNA in paper 2. Importantly, our results showed that the 
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interaction is mediated by APIM and that proper function of XPA for UV damage repair 
is dependent on interaction with PCNA. Our data indicates that the interaction between 
XPA and PCNA takes place in replication foci, although NER is considered to be 
replication independent. Thus, interaction at the replication foci might be an artifact of 
overexpression due to direct interaction, enabling overexpressed PCNA to transport 
overexpressed XPA to these foci. Alternatively, XPA might in fact have an important 
role close to the replication fork. Bulky adducts and crosslinks block replication 
(Kaufmann, 2007; Unsal-Kacmaz et al., 2007; Wang and Lippard, 2005). Thus, keeping 
the NER core protein XPA in front of the replication fork could enable pre-replicative 
NER removal of the crosslink, allowing progression of the replication. The TLS 
polymerases may bypass the same bulky adducts, however, in an error-prone manner 
(Loeb and Monnat, 2008). NER, on the other hand has generally been considered to be 
error-free (Wood and Shivji, 1997; Youngs and Smith, 1973), although this has recently 
been challenged (Ogi et al., 2010). Ogi and colleagues suggest that not only Pol δ and 
Pol ε but also the “sloppy” TLS polymerase Pol κ may participate in the repair synthesis 
step in NER. Nevertheless, the presence of replication coupled repair by NER would be 
beneficial for the genome integrity. The confocal images show a clear colocalization 
between XPA and PCNA (paper 2), but compared to hABH2 (paper 1), more XPA 
seems to be in the nucleoplasm, indicating that only a fraction of the available XPA 
binds to PCNA. XPA may therefore have more than one role in the cell, which may 
mirror the contradictory published material concerning both the function as well as the 
cellular localization of XPA (Asahina et al., 1994; Bartels and Lambert, 2007; Lambert 
and Yang, 2000; Luijsterburg et al., 2010; Rademakers et al., 2003; Wu et al., 2007).  
The BER/SSBR complexes appear to be comprehensive and intricate, and whether the 
BER/SSBR repair foci are pre-formed or formed sequentially upon DNA damage is part 
of an ongoing debate (Akbari et al., Unpublished; Akbari et al., 2010; Dianov et al., 
2003; Fan and Wilson, 2005). Both XRCC1 and PCNA can be referred to as scaffolding 
proteins, since they have no enzymatic activity but instead mainly exert their effects 
through interaction with other proteins. PARP1 is reported to be important in BER, 
mainly through its recognition and binding to single strand breaks (Caldecott, 2008); 
however, recent work in our group suggests that PARP1 is important for recruitment of 
 55
long patch BER proteins (Akbari et al., Unpublished). PARP1 is reported to bind to the 
internal NLS-BRCT1 mutant of XRCC1 (Masson et al., 1998), the mutant required for 
complementation of XRCC1 in alkylation damage repair (paper 3). However, the C-
terminal mutant, which also possesses the binding site for PARP1, did not have the 
capacity to complement for XRCC1. Thus, SSB recognition or recruitment of long 
patch repair proteins is not likely to be important in this case. It is more likely that the 
internal mutant’s ability to bind to PCNA and MPG is its cardinal trait in 
complementation of XRCC1 in alkylation damage repair. It has recently been shown 
that the repair of alkylation damage from MMS, primarily executed by BER, is essential 
for fork progression during replication, at least in yeast (Vazquez et al., 2008). 
Moreover, MPG has been reported to be up-regulated in the S-phase and to interact with 
PCNA through an “inverted” PIP-box (Bouziane et al., 2000; Xia et al., 2005). This 
supports that the function of this protein is dependent on binding to PCNA, apparently 
recruited by XRCC1.  
The potential binding of OGG1, NEIL2 and NTH1 to the same internal XRCC1 
deletion mutant during exposure to oxidative damage from hydrogen peroxide did not 
support repair. This may indicate that repair of oxidative damage is not linked to 
replication to the same extent as the repair of alkylation damage, or that the main 
products of hydrogen peroxide treatment are SSBs. OGG1 has previously been reported 
to be constitutively expressed throughout the cell cycle (Dhenaut et al., 2000), whereas 
NEIL2 and NTH1 are reported to be up-regulated during S-phase (Hazra et al., 2002; 
Luna et al., 2000), and NTH1 to interact with PCNA (Oyama et al., 2004). A study has 
shown that knock down of both OGG1 and NTH1 individually, sensitized cells to 
hydrogen peroxide, demonstrating that this is a substrate recognized by these 
glycosylases (Yang et al., 2006). However, Yang and colleagues used ~100× more 
hydrogen peroxide compared to what we used in our comet assays. This dose would 
have wiped out our XRCC1 deficient cells, but perhaps a higher dose of hydrogen 
peroxide gives more oxidative damage.   
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PTMs  on  PCNA  mediate  the  binding  of  APIM  containing  proteins, 
possibly  inducing  DNA  repair,  cell  cycle  arrest,  and  re‐adjustments  in 
transcription 
We found that the PCNA form pulled down by APIM was modified (paper 1), and we 
are currently working on identification of this PTM. Compared to the main form of 
PCNA (pulled down by anti-PCNA antibodies), the form pulled down by APIM had a 
rare modification, making PCNA slightly more basic but not much larger. Thus, it is not 
likely that this modification is an ubiquitylation which is reported to signal the switch 
from a replicative to a TLS polymerase upon arrest of the replication fork (Lee and 
Myung, 2008). It is more likely that this modification is an acetylation, a PCNA 
modification reported to be enriched in the chromatin bound fraction and up-regulated 
during S-phase (Naryzhny and Lee, 2004). Thus, this modification fits well with our 
data; however, we have not been able to identify any acetylations on PCNA by Western 
blots. In terms of charge and size, the APIM specific modification also resembles the 
reported cancer specific methyl esterification on PCNA (Hoelz et al., 2006); however, 
APIM containing proteins also interact with PCNA in noncancerous cells. We believe 
that APIM specific PTM modification of PCNA may be induced by DNA damage, 
signaling a switch in PCNA’s binding preference from PIP-box containing proteins, to 
APIM containing proteins as illustrated in figure 8. This will explain why APIM 
expression sensitized cells to DNA damaging agents, whereas unthreated cells seemed 
to be unaffected by APIM (paper 1 and 2).  
 
Figure 8. Suggested change in PCNA’s affinity towards PIP-box containing 
proteins (orange) to affinity towards APIM containing proteins (blue) as a result 
of APIM specific PTMs on PCNA after DNA damage. Expression of the APIM 
peptide (small blue dots) blocks the binding of APIM containing proteins to 
PCNA. 
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Cells overexpressing APIM are hyper-sensitive to crosslinking agents such as 
Carmustine/BCNU and Mitomycin C (paper 1) as well as cisplatin (unpublished data), 
forming intrastrand crosslinks and ICLs. The cellular response to these crosslinks 
involves several processes including cell signaling and activation of various DNA repair 
pathways such as NER, HR, FA and TLS (Wang and Lippard, 2005; Wang, 2007). 
Impaired function of XPA may contribute to the increased sensitization to crosslinks; 
however, we did not observe any sensitization to cisplatin when we knocked down XPA 
by siRNA. It is not likely that diminished hAHB2 affects the sensitization to these 
agents; however, reduced function of RAD51B may reduce the efficiency of HR and 
thereby the error-free ICL repair. Moreover, the reason for APIM’s sensitization to 
crosslinking agents is probably imputable to reduced function of several of the APIM 
containing proteins listed in http://tare.medisin.ntnu.no/pcna/index.php, published in 
paper 1. Among these are the HR proteins pro-BRE and hSMC5, and the FA protein 
FANCC mentioned previously. Preliminary studies regarding the core FA protein 
FANCC show that FANCC colocalizes with PCNA, possibly through a functional 
APIM motif (Müller et al., in prep). Also, the MAP kinase pathway contains three 
APIM containing proteins; MAPKAP Kinase 2 and 5 (MK2 and MK5) and mitogen-
activated protein kinase 15. MK2 is known to be activated upon cell stress including 
DNA damage (Kyriakis and Avruch, 2001), and a recent study has suggested a role for 
MK2 in cell cycle arrest in response to DNA damage (Reinhardt and Yaffe, 2009). An 
ongoing study at our lab suggests that the MAP-kinase pathway is partly impaired by 
overexpression of APIM, possibly contributing to the sensitization to crosslinking 
agents (Müller et al. in prep).  
The transcription machinery controls and adjusts the protein production according to the 
cells’ demand. After cell stress such as DNA damage, transcription of stress-related 
genes is stimulated while transcription of growth-related genes is repressed (Lopez-
Maury et al., 2008). In paper 1, our strongest evidence for the functionality of APIM as 
a PCNA interacting motif was the transcription factor TFII-I with four conserved 
functional APIM motifs. TFII-I is a growth factor induced transcription factor which 
has been shown to participate in transcription of Cyclin D1, which is important for cell 
cycle entry into S-phase as a response to growth signal (Desgranges and Roy, 2006). 
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Vice versa, the same group suggested that TFII-I is ubiquitylated and degraded 
following genotoxic stress, resulting in repression Cyclin D1 transcription and thereby 
cell cycle arrest. Thus, a presence of TFII-I in front of the replication fork would 
efficiently sense the DNA damage and signal for cell cycle arrest. Furthermore, two 
RNA polymerase II subunits contain APIM, whereas the largest subunit (RPB1) has 
shown to colocalize with PCNA in replication foci (Halvei, 2009, unpublished Master 
thesis). This supports a close interaction between DNA replication and transcription, 
which has already been suggested (Gilchrist et al., 2008; Malyavantham et al., 2008). A 
close interaction between these two processes, which previously was referred to as 
separate (Wei et al., 1998), enables communication of replication arrest upon 
encountering of DNA damage. This may lead to transcription repression of growth-
related genes, while transcription of stress-related genes may be stimulated. Our data 
from paper 1, suggests that APIM could be important in this linkage between DNA 
replication and transcription, possibly signaled by APIM-specific PTMs on PCNA.   
In vivo versus in vitro approach for the study of protein complexes 
Traditionally, protein interactions have been studied in vitro, inside a tube. Our 
approach; however, has been to identify protein-protein interactions and protein 
localization in live cells in vivo. Many of our results could not be obtained from purified 
proteins and in vitro experiments. Examples are our endless unsuccessful attempts to 
show specific binding between purified full length hABH2 and PCNA in vitro, before 
we realized that the PCNA form binding to APIM is PTM modified. Thus, specific high 
affinity interaction is likely dependent upon this modification. XRCC1 is similar to 
PCNA, a scaffold protein which is PTM modified. The exact nature and extent of PTM 
modifications on XRCC1 and PCNA are not fully understood. However, proper protein 
modifications as well as correct intra-cell and intra-nuclear localization are vital in order 
to study and identify new interaction partners. 
In cases where the alternative PTMs are known and can be mimicked, in vitro assays 
can be useful. If we can mimic the specific PTM required for APIM’s binding to PCNA, 
we can execute in vitro assays to quantitatively elucidate the stimulatory effect of 
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hABH2’s binding to PCNA. However, whether the binding between hABH2 and PCNA 
increases the activity of hABH2 in a reaction tube where the enzyme and substrate are 
in close proximity is uncertain. Another urgent issue that needs to be addressed is to 
elucidate where on PCNA the APIM motif binds. If we manage to acquire specific in 
vitro binding between APIM and PCNA, they can be crystallized together, or 
alternatively be analyzed by Small angle X-ray scattering (SAXS) experiments. The 
PIP-box has been reported to bind into a hydrophobic pocket of PCNA buried under the 
interdomain connecting loop (Bruning and Shamoo, 2004; Gulbis et al., 1996), and 
whether the APIM-peptide binds to or overlap with this loop is of interest since this 
could tell us whether PIP and APIM collaborate and mutually exclude each other.  
APIM versus PIP  
For 11 years (Warbrick, 1998), the PIP-box was the only known PCNA interacting 
motif, and in many papers we find the sentence “…PIP box, was found in … and most 
other PCNA-binding partners” (Moldovan et al., 2007). In fact, in the database search 
performed for paper 1, we found 226 nuclear proteins with conserved APIM and “only” 
198 with conserved PIP-box, indicating that at least as many proteins contain the APIM 
motif. The functionality of PIP and APIM in most of these proteins, however, remains 
to be determined. The majority of the PIP-containing proteins are directly involved in 
DNA replication or in processes tightly bound to the replication such as the MMR 
pathway. On the other hand, APIM containing proteins appear to be involved in 
processes more important after cell stress. In support for this, overexpression of a PIP-
box peptide (from p21) completely blocked DNA replication (Mattock et al., 2001), 
while overexpression of APIM had little or no effect on the cell growth without addition 
of cytotoxic agents (paper 1 and 2).  
APIM Therapeutics AS 
The APIM motif is now being patented, and a company APIM Therapeutics AS, has 
been established. Exposing various cancer cells to an APIM-derived peptide has shown 
that the toxic effect of APIM alone is a matter of concentration. Also, the toxicity varies 
significantly between different cancer cells. Certain cancer cell lines, such as lymphoma 
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and myeloma cells, are particularly sensitive to the peptide without additional drugs, 
whereas other cancer cell lines such as osteosarcoma and breast cancer cells appear to 
be unaffected by APIM expression alone, but display an increased sensitivity when 
exposed to APIM in combination with cancer chemotherapy. Moreover, preliminary 
studies using a Xenograft prostate cancer mouse model have shown that the mice 
receiving the APIM peptide together with cisplatin displayed delayed tumor growth. 
Importantly, the APIM motif is not toxic to the mice as judged by body weight loss at 
receivable doses; thus, the APIM-peptide has a potential as a DNA repair modulator in 
future cancer treatment.  
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Introduction
Proliferating cell nuclear antigen (PCNA) is a member of 
the conserved sliding clamp family of proteins. It is essential 
for chromosomal DNA replication and important for several 
DNA transactions, such as DNA repair, epigenetic modifica-
tion, chromatin assembly and remodeling, sister chromatid 
cohesion, and cell cycle control (Moldovan et al., 2007). Nu-
merous proteins involved in these processes are localized in 
so-called replication factories, and many of these proteins 
interact with PCNA through the conserved sequence called the 
PCNA-interacting peptide (PIP) box (QxxL/I/MxxHF/DF/Y; 
Warbrick, 2000). However, several PCNA-binding proteins 
do not contain a PIP box (Fan et al., 2004; Moldovan et al., 
2007). Furthermore, posttranslational modifications (PTMs) 
of PCNA have been reported to regulate the affinity to its 
binding partners, as illustrated by polymerase switch (Lehmann 
et al., 2007).
Human cells are exposed to alkylating compounds pro-
duced endogenously from environmental sources and drugs 
used in cancer treatment (Drabløs et al., 2004). Proteins 
involved in DNA repair and cell cycle control are interesting 
targets to increase the efficacy of chemotherapy (Helleday 
et al., 2008). The DNA damage introduced, such as alkylation 
adducts and interstrand cross-links, may lead to miscoding, 
replication arrest, double-strand breaks, and/or cell death. The 
simpler lesions, such as methylated bases, are repaired by base 
excision repair (BER), oxidative demethylation, or methyl 
transfer, depending on the type of damage (Sedgwick et al., 
2007). The BER enzyme 3-methyladenine DNA glycosylase 
(AAG/MPG; removes 3meA) and the oxidative demethylase 
human AlkB homologue 2 (hABH2; repairs 1meA and 3meC) 
are both localized in proximity of replication foci (Aas et al., 
2003; Xia et al., 2005). Although MPG contains an “inverted” 
PIP box sequence for interaction with PCNA, no PIP box is 
found in hABH2.
In this study, we demonstrate that hABH2 interacts with 
PCNA through a novel PCNA-interacting motif, AlkB homo-
logue 2 PCNA-interacting motif (APIM), and that APIM is a 
functional PCNA-binding motif important for several proteins 
involved in DNA maintenance and cell cycle regulation after 
DNA damage.
 Numerous proteins, many essential for the DNA replication machinery, interact with proliferating cell nuclear antigen (PCNA) through the PCNA-
interacting peptide (PIP) sequence called the PIP box. We 
have previously shown that the oxidative demethylase 
human AlkB homologue 2 (hABH2) colocalizes with PCNA 
in replication foci. In this study, we show that hABH2 inter-
acts with a posttranslationally modified PCNA via a novel 
PCNA-interacting motif, which we term AlkB homologue 2 
PCNA-interacting motif (APIM). We identify APIM in 
>200 other proteins involved in DNA maintenance, tran-
scription, and cell cycle regulation, and verify a functional 
APIM in five of these. Expression of an APIM peptide 
increases the cellular sensitivity to several cytostatic agents 
not accounted for by perturbing only the hABH2–PCNA 
interaction. Thus, APIM is likely to mediate PCNA binding 
in many proteins involved in DNA repair and cell cycle 
control during genotoxic stress.
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Tyr could substitute for Phe at this position, whereas Ala abol-
ished the interaction (Fig. 2 B and not depicted). We verified 
the sequence specificity for the PCNA interaction in vivo by 
expressing the conserved amino acids 1–7 of hABH2, and vari-
ants in which Phe4 was substituted by Tyr, Trp, or Ala, in fusion 
with YFP and tested their subnuclear localization. Expressed 
fusion proteins containing an aromatic amino acid in position 4 
colocalized with PCNA when expressed alone (Fig. 2 C, rows 
1 and 2) and when coexpressed with CFP-PCNA (Fig. 2 C, 
rows 3–5). Analogous to what was found in dot blot assays, the 
F4A mutation severely reduced the colocalization with PCNA 
(Fig. 2 C, row 6). By measuring fluorescence resonance energy 
transfer (FRET), we found that both full-length hABH2-YFP 
and hABH21–10-YFP as well as hABH21–7F4W-YFP are in very 
close proximity with CFP-PCNA because fluorescent tags must 
be <100 Å apart to give positive FRET (Mátyus, 1992).
To further investigate the proximity between hABH2 and 
PCNA, we performed in vivo cross-linking in cells stably ex-
pressing hABH21–7-YFP-Flag and hABH21–7F4A-YFP-Flag 
using formaldehyde. Formaldehyde induces heat-reversible cross-
links of proteins that are within 2 Å of one another (Vasilescu 
et al., 2004). Extracts from these cells were used for IP with -Flag. 
After elution with Flag peptide, cross-links in half of the samples 
were reversed. In Fig. 2 E (lanes 3 and 11), bands containing both 
PCNA and Flag are identified at molecular masses of 70–75 kD 
(1: PCNA cross-linked to hABH21–7-YFP-Flag), 100–130 kD 
(2: PCNA dimer or trimer cross-linked to hABH21–7-YFP-Flag), 
and 160–190 kD (3: PCNA trimer cross-linked to two or three 
hABH21–7-YFP-Flag). Bands 1 and 2 are much stronger in the 
IP from cells expressing hABH21–7 wild type (WT) than from 
cells expressing the hABH21–7F4A mutant, and band 3 is not de-
tected in the IP from cells expressing the hABH21–7F4A mutant. 
Notably, after reversal of the cross-links (lanes 4 and 12), only 
PCNA and Flag bands of 35 kD were identified, suggesting that 
the larger bands detected in lanes 3 and 11 were cross-linked with 
hABH21–7-YFP-Flag and PCNA. Together with the FRET, these 
data strongly support a direct interaction between hABH21–7  
and PCNA.
Our data from co-IP experiments (Fig. 1, B–D) indi-
cated that more complexes of hABH2 and PCNA were pulled 
down from chromatin-enriched fractions, suggesting potential 
involvement of PTMs. Therefore, we analyzed the isoform 
distribution of PCNA cross-linked to hABH21–7-YFP-Flag 
by 2D Western blot (WB) analysis and compared it with the 
total repertoire of PCNA isoforms present in the same cell 
extract (Fig. 2 F). We included purified RAD51 as an inter-
nal standard because its isoelectric point (pI; 5.4) is close to 
the pI of unmodified PCNA (4.6). Our results indicate that 
the PCNA variants cross-linked to hABH21–7-YFP-Flag (top 
membrane) are shifted toward a more acidic pI without sig-
nificantly changing the vertical migration. Multiple isoforms 
of PCNA with pI between 4 and 5 have previously been identi-
fied, although the exact nature of most of these modifications 
is not known (Naryzhny, 2008). Most PCNA present in a cell 
(lower membrane), and the low levels (Fig. 2 E, lane 7) of 
PCNA cross-linked to hABH21–7F4A-YFP-Flag (mutant; mid 
membrane), have a higher pI than the PCNA pulled down by 
Results and discussion
The 10 N-terminal amino acids in hABH2 
are essential for colocalization with PCNA
To identify the region in hABH2 responsible for localization in 
replication foci during S phase (Aas et al., 2003), we coexpressed 
PCNA tagged with a blue variant of GFP (CFP-PCNA) and var-
ious hABH2 deletion mutants fused with a yellow GFP variant 
(YFP) because GFP-tagged PCNA is known to form foci rep-
resenting sites of replication (Leonhardt et al., 2000). First, we 
verified that hABH2-YFP colocalized with endogenous PCNA 
similar to coexpressed, tagged PCNA (Fig. 1 A, rows 1 and 2). 
Next, we found that deletion of the 10 N-terminal amino acids 
in hABH2 totally abolished the colocalization with PCNA. 
Remarkably, these 10 amino acids fused to YFP were sufficient 
for colocalization with PCNA (Fig. 1 A, rows 3 and 4). No-
tably, coexpression of CFP-PCNA increased the localization 
of full-length hABH2 (hABH21–261-YFP) but not hABH211–261-
YFP in nuclear foci, suggesting a direct interaction between 
PCNA and hABH2 mediated by the 10 N-terminal amino 
acids of hABH2.
To investigate the potential hABH2–PCNA interaction in 
more detail, soluble and chromatin-enriched protein extracts were 
prepared from cells expressing hABH2-YFP, hABH211–261-YFP, 
or YFP and subjected to coimmunoprecipitation (co-IP) using 
anti-YFP antibodies (-YFP). Notably, low levels of PCNA 
were pulled down from the soluble cell fraction, whereas PCNA 
was readily pulled down from the chromatin-enriched fraction. 
Moreover, removal of the 10 N-terminal residues in hABH2 
markedly decreased the amount of PCNA pulled down (Fig. 1 B). 
The hABH2–PCNA interaction was confirmed by reciprocal 
experiments using extracts from cells expressing YFP-PCNA 
(Fig. 1 C) and also by targeting endogenous PCNA (Fig. 1 D). 
In both cases, more hABH2 was pulled down from the chromatin-
enriched fractions than from the soluble fractions (Fig. 1, C 
and D), even though both proteins were present in the soluble frac-
tion (Fig. 1 D, input). Collectively, these results support the idea 
that hABH2 interacts with PCNA and that the binding sequence 
is contained within hABH2’s 10 N-terminal amino acids. The 
apparent preferential association of hABH2 and PCNA in the 
chromatin-enriched fraction may indicate that a subfraction of 
either of the proteins exists in a PTM form, promoting the inter-
action. Alternatively, the presence of other proteins may medi-
ate the observed interaction. A bridging effect caused by DNA 
interaction was considered less likely because the chromatin-
enriched fraction was subjected to extensive DNase and RNase 
treatment before co-IP.
hABH2 directly interacts with PCNA 
through a novel PCNA-binding motif
Sequence alignment of ABH2s from several species shows 
that the seven N-terminal amino acids are highly conserved 
(Fig. 2 A) and have the apparent consensus Met-Asp-Lys/Arg-
Phe-(Leu/Val/Ile)2-Lys/Arg. The flanking amino acids (8–10) 
are not conserved. Dot blot assays against mutant versions of 
this sequence indicated that the most important determinant for 
binding to PCNA was an aromatic residue at position 4 because 
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hABH21–7-YFP-Flag. PTMs on PCNA may explain why our 
attempts to analyze the PCNA–hABH2 interactions using puri-
fied recombinant full-length proteins in in vitro experiments 
gave inconclusive data.
Collectively, these results reveal a novel PCNA-binding 
site within the conserved seven N-terminal amino acids of 
hABH2. Based on the alignment of the different ABH2s, the dot 
blot assay, and the in vivo imaging results, APIM was defined as 
[KR]-[FYW]-[LIVA]-[LIVA]-[KR].
Overexpression of APIM decapeptide 
fused to YFP reduces repair of 1meA and 
sensitizes cells to DNA alkylation damage
hABH2 is known to repair 1meA and 3meC generated by the 
SN2-alkylating agent methyl methanesulfonate (MMS) (Aas 
et al., 2003; Ringvoll et al., 2006). To examine whether expres-
sion of APIM interfered with the function of hABH2 by per-
turbation of the PCNA binding, we exposed cells expressing 
hABH21–10-YFP or only YFP to MMS and analyzed removal 
of 1meA in DNA by liquid chromatography (LC)/mass spec-
trometry (MS)/MS. Cells were arrested at the G1/S border 
and treated with MMS for 1 h. For arrested cells, a 13% sig-
nificant increase of 1meA was seen in APIM-YFP–expressing 
compared with YFP-expressing cells (Fig. 3 A). This is likely 
the result of reduced removal of 1meA by endogenous hABH2 
during incubation with MMS. These results indicate that the 
hABH2–PCNA interaction is required for efficient removal of 
1meA in cells arrested at the G1/ S transition.
Next, we exposed cell lines expressing hABH21–10-YFP, 
hABH21–7F4A-YFP, and YFP to MMS and measured their 
colony-forming capacity. We found a fivefold decrease in colony-
forming units in cells overexpressing functional hABH21–10-YFP 
compared with the cells expressing mutated APIM and only 
YFP (Fig. 3 B). These results strongly suggest that binding of 
APIM to PCNA increases MMS cytotoxicity. We subsequently 
exposed hABH21–10-YFP– and YFP-expressing cells to MMS 
as well as three other alkylating agents, BCNU (carmustine), 
temozolomide (TMZ), and mitomycin C (MMC), and measured 
cell growth for 4 d (MTT assay [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide]). Unlike MMS, the other 
alkylating agents are believed to introduce damage not repaired 
by hABH2 but by several different repair pathways, includ-
ing direct methyl transfer by O6-methylguanine-DNA methyl-
transferase, nucleotide excision repair, BER, mismatch repair, 
and homologous recombination (Sedgwick et al., 2007). Over 
expression of hABH21–10-YFP had little effect on the growth 
rate in untreated cells, whereas it strongly sensitized cells to all 
the alkylating agents (Fig. 3 C). These results suggested that 
the hypersensitivity to genotoxic agents was caused by inhibit-
ing the function not only of hABH2 but also of other proteins 
involved in genome maintenance.
Figure 1. The 10 N-terminal amino acids of hABH2 are important for 
interaction with PCNA. (A) Confocal fluorescence images of full-length 
hABH2-YFP with endogenous PCNA (row 1) and hABH2 constructs co-
expressed with CFP-PCNA in live cycling HeLa cells. Insets show a higher 
magnification view of boxed regions. Bar, 5 µm. (B) Co-IP of PCNA from 
HeLa cells stably expressing hABH2-YFP constructs using -YFP beads. 
(C) Co-IP of hABH2 from cells stably expressing YFP-PCNA using -YFP 
beads. (D) Co-IP of hABH2 from cells only expressing endogenous proteins 
using -PCNA beads. Input is 3.3% of cell extract used for IP. Black lines, 
separate membranes; gray lines, same membranes.
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Figure 2. Close interaction between the N terminus of hABH2 and a modified form of PCNA. (A) Sequence alignment of the 10 N-terminal amino acids 
of ABH2 homologues from different species (colors as given by Clustal X). (B) PCNA binding to hABH21–10 peptide variants (dot blot). Row 1 shows the 
hABH21–10 peptide, and rows 2–8 show peptides where different amino acids are substituted (underlined in the right panel; data from one membrane). 
(C) Confocal images of HeLa cells. Row 1 shows hABH21–7-YFP expressed alone (live cells), row 2 shows hABH21–7-YFP with endogenous PCNA, and 
rows 3–6 show various hABH21–7-YFP F4 variants coexpressed with CFP-PCNA (live cells). Insets show a magnified view of the boxed areas. Bars, 5 µm. 
(D) NFRET measurements. YFP/CFP (vectors only) and YFP-PCNA/CFP-PCNA were used as background and positive controls, respectively. Data shown 
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either one of the four APIMs of TFII-I, did not cause visible 
reduction in colocalization with PCNA when cotransfected 
with PCNA alone (unpublished data), but a reduction in FRET 
could be detected in these cases (Fig. 4 B, green). Thus, higher 
FRET between PCNA and WT proteins, and the fact that WT 
proteins outcompete the mutant proteins for binding to PCNA 
when coexpressed (Fig. 4 A, rows 3 and 4), suggested that the 
affinity of the mutant proteins for PCNA was reduced. Only a 
minor reduction in colocalization with PCNA was observed for 
the mutant Topo II  when coexpressed with WT Topo II . 
However, a reduction in FRET was also detected in this case 
(Fig. 4 B). Because Topo II  is a homodimer (Nettikadan et al., 
1998), binding to PCNA could be mediated through its non-
mutated endogenous or coexpressed WT partner. Altogether, 
these results strongly suggest that APIM is a functional PCNA- 
binding motif in all these proteins.
The RAD51B S phase spots were on average less bright 
than the spots for the other APIM-containing proteins, and 
clear colocalization with PCNA was seen in only 20% of the 
S phase cells in comparison with 95–100% for hABH2, TFIIS-L, 
TFII-I, and Topo II . This indicates that the PCNA–RAD51B 
interaction is less prominent and might require specific cell 
conditions.
In summary, the work presented in this study strongly indi-
cates that APIM is a functional, widespread PCNA-interacting 
motif found in many proteins involved in genome maintenance. 
Among other interesting APIM-containing proteins are the 
poly(ADP-ribose) family (PARP-1, -2, and -4), the FANCC pro-
tein, the REV3L subunit of translesion polymerase , several E3 
ubiquitin protein ligases, subunits of the general transcription 
factors II and III, members of the MAPK pathway, many serine/
threonine protein kinases, and three subunits of RNA poly-
merase II and III (Table I). Interestingly, recent data indicate 
a partial overlap between regions of replication and transcrip-
tion (Malyavantham et al., 2008); thus, APIM could possibly 
be involved in linking transcription and cell cycle regulation to 
PCNA/replicative processes after genotoxic stress.
The scaffold protein PCNA interacts with numerous pro-
teins in a well-orchestrated fashion, thus constituting a foun-
dation for many vital cellular processes. Interactions with PCNA 
are likely to be regulated at several levels; e.g., by PTMs as 
well as through several PCNA-interacting motifs (Moldovan 
et al., 2007). Interestingly, PCNA-binding peptides containing 
the PIP box fused to GFP are reported to block colony forma-
tion when expressed in untreated freely cycling HeLa and 
U2OS cells (Warbrick, 2006). Cells expressing APIM-YFP 
had normal capacity for colony formation in untreated cells, 
but these cells showed increased sensitivity to alkylating agents. 
We suggest that impaired PCNA binding of several APIM-
containing proteins, in addition to hABH2, contributes to the 
APIM is found in many proteins involved in 
genome maintenance and cell cycle control
Using the APIM motif as the query, we obtained 636 hits in the 
Swiss-Prot/TrEMBL database. After discarding nonnuclear 
proteins and proteins in which APIM is not conserved, this was 
reduced to 226 hits (Table I; see http://tare.medisin.ntnu.no/
pcna/index.php for complete query results and experimental 
procedures). Nine of these proteins also contained the PIP box 
consensus (Table I).
Among the proteins found in the query, we examined the 
APIMs more closely in four human proteins in addition to 
hABH2. We named the first protein examined TFIIS-like 
(TFIIS-L) because it contains the conserved N-terminal do-
main I found in elongation factor TFIIS (Cramer, 2004). The 
function of this protein is unknown. However, like hABH2, 
TFIIS-L contains an APIM within its seven N-terminal amino 
acids. We next examined the multifunctional transcription fac-
tor TFII-I, which contains four APIMs. TFII-I is a transcription 
factor critical for cell cycle control and proliferation and has 
also recently been suggested to have a role in DNA repair 
(Desgranges and Roy, 2006). Finally, we examined APIM in 
DNA topoisomerase (Topo) II , which is involved in post-
replicative DNA decatenation and DNA segregation (Agostinho 
et al., 2004), and the RAD51 paralogue RAD51B, which is in-
volved in homologous recombination, centrosome function, 
and chromosome segregation (Date et al., 2006). The APIM 
sequences in all these proteins are conserved throughout evolu-
tion (Fig. 3 D). Among these proteins, only Topo II  has been 
reported to localize to nuclear S phase foci (Lou et al., 2005) 
and to contain a putative PIP box (QttLaFkp; amino acids 
1,277–1,284; Niimi et al., 2001). We cloned the proteins as 
YFP fusions and found that all were nuclear proteins accumu-
lating in various numbers of visible foci (Fig. 3 D), many of 
which represent replication foci (see following paragraph). 
Endogenous TFII-I was also present in foci colocalizing with 
endogenous PCNA (unpublished data).
APIM is a functional  
PCNA-interacting motif
Substitution of Phe4 to Ala in APIM impaired binding between 
hABH2-derived peptides and PCNA (Fig. 2); thus, we wanted 
to examine whether the corresponding mutation had a similar 
effect on the full-length hABH2, TFIIS-L, TFII-I (in one and 
four APIMs), Topo II , and RAD51B. Mutation of APIM in all 
these proteins, except Topo II , strongly reduced colocaliza-
tion with PCNA when coexpressed with WT proteins (Fig. 4 A, 
rows 2–7), suggesting that impaired APIM reduced the PCNA 
interaction. However, coexpression of WT hABH2-CFP and 
WT hABH2-YFP resulted in foci containing both fusion pro-
teins (Fig. 4 A, row 1). Mutations of APIM in TFIIS-L, or in 
are the result of three individual experiments (mean ± SEM; n = 35–50). (E) Cross-linked and reverse cross-linked IPs (-Flag) from cells stably expressing 
hABH21-–7YFP-Flag and hABH21-–7F4A-YFP-Flag. The eluted fractions were analyzed for the presence of PCNA and Flag fusion proteins by WB. (F) 2D gel 
electrophoresis followed by WB analysis of PCNA immunoprecipitated from cross-linked hABH21–7-YFP-Flag (top membrane; -Flag) and hABH21–7F4A-
YFP-Flag (mid membrane; -Flag). Total PCNA was immunoprecipitated with -PCNA beads (lower membrane). Purified recombinant RAD51 (rRAD51) 
was added as an internal standard. Dotted lines illustrate the vertical alignment of the membranes. (B and E) Gray lines indicate that intervening lanes 
have been spliced out.
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hypersensitivity to cytostatic drugs seen in APIM-expressing 
cells and that coordinated binding of APIM-containing pro-
teins to PCNA might be an important response mechanism 
subsequent to DNA damage.
Materials and methods
Expression constructs
Cloning of the fluorescently tagged expression constructs CFP-PCNA, 
Hereactis crispa RFP (HcRed)–PCNA, and hABH21–261-YFP/-CFP has 
been described previously (Aas et al., 2003; Otterlei et al., 2006). 
Using phABH21–261-YFP as a template, phABH21–10-YFP and phABH211–261- 
YFP were generated by PCR and cloned into pYFP-N1 (Clontech Lab-
oratories, Inc.) using NdeI–AgeI and AgeI–EcoRI, respectively. The 
PCR product from EST (image clone 5176979 [BC035374] Resource 
Center/Primary Database) was cloned into pYFP- and pCFP-C1 
(HindIII–Acc651) to make pYFP- and pCFP–TFIIS-L. pTFII-I–YFP and –CFP 
were generated by PCR amplification of TFII-I from pI3CX–TFII-I (pro-
vided by R.G. Roeder, The Rockefeller University, New York, NY) and 
cloning into pYFP- and pCFP-N1 (SacI–ApaI). pYFP– and pCFP–Topo II  
were made by switching the EGFP tag (EcoRI blunt–NheI) with YFP and 
CFP tag (XhoI blunt–NheI) from pEGFP–Topo II  (pT104-1; provided by 
Figure 3. Expression of APIM decapeptide sensitizes cells to alkylating agents, and several foci-forming proteins contain conserved APIM. (A) 1meA in 
DNA isolated from YFP (closed squares)- and hABH21–10-YFP (open circles)–expressing cells after exposure to 1.2 mM MMS for 1 h before release from 
the G1/S border (mean ± SEM; n = 4–5). (B) Clonogenic assay comparing the MMS sensitivity between cells expressing hABH21–10-YFP (open circles), 
hABH21–7F4A-YFP (closed triangles), or only YFP (closed squares; mean ± SD; n = 2–4). CFU, colony-forming unit. (C) Cell growth of HeLa cells stably 
expressing YFP (closed squares) and hABH21–10-YFP (open circles) measured by MTT assay after continuous exposure to MMS, BCNU, MMC, and TMZ. 
The growth rates of unexposed cells are shown in the right lane. (D) Conservation of APIM in TFIIS-L, TFII-I, Topo II , and RAD51B. These proteins are 
shown as YFP fusion proteins. Bar, 5 µm.
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W.T. Beck, University of Illinois, Chicago, IL). RAD51B was amplified by 
PCR from pET15b-RAD51B (provided by S. Yokoyama, RIKEN Genomic 
Sciences Center, Kanagawa, Japan) and cloned into pYFP- and pCFP-N1 
using XhoI and SacII. The hABH21–7-YFP constructs, including the F4 
mutants, were made by annealing oligos with XhoI–EcoRI overhang 
followed by cloning into pYFP-N1 mutated in the ATG codon. The Flag 
constructs were generated by PCR amplification of the 3× Flag tag from 
p3×Flag–CMW-14 (Sigma-Aldrich) followed by cloning into pCFP-N1 
in the BsrGI–XbaI site. All point mutations were made by site-directed 
mutagenesis (QuickChange II; Agilent Technologies) according to the 
manufacturer’s instructions. Restriction enzymes and calf intestinal alka-
line phosphatase were obtained from New England Biolabs, Inc., and 
the oligonucleotides were obtained from MedProbe Eurogentech. All con-
structs were verified by sequencing.
Confocal imaging
HeLa cells were examined 16–48 h after transient transfection (by 
Fugene 6 [Roche] or Lipofectamine 2000 [Invitrogen] according to the 
manufacturer’s recommendations) of CFP, YFP, and HcRed fusion con-
structs. Fluorescent images were aquired using a laser-scanning micro-
scope (LSM 510 Meta; Carl Zeiss, Inc.) equipped with a Plan Apochromat 
63× 1.4 NA oil immersion objective. The images were acquired in the 
growth medium of the cell with the stage heated to 37°C using LSM 510 
software (Carl Zeiss, Inc.). For the two-color images, CFP was excited at 
 = 458 nm and detected at  = 470–500 nm, and YFP was excited at 
 = 514 nm and detected at  = 530–600 nm using consecutive scans. 
When three-color images were acquired, YFP was excited at  = 488 nm 
and detected at  = 530–600 nm, HcRed was excited at  = 543 nm 
and detected at  > 560 nm, and the CFP settings were kept as for the 
Table I. Selected proteins containing APIM
Type/group of proteins Proteins Source
Proteins containing PIP box  
and APIM
DNA ligase I, MDN1 Midasin, ubiquitin thioesterase FAF-X,  
 protein 18 homologue (hVPS18), cytokine signaling 6 (SOCS-6),  
 Topo II , IB-related protein, UHRF2, PARP4
Moldovan et al., 2007
DNA polymerase Pol  catalytic subunit (hREV3L) Moldovan et al., 2007
DNA ligases DNA ligase I, DNA ligase IV Moldovan et al., 2007
Topo Topo II  and  This study; Niimi et al., 2001;  
 Lou et al., 2005 
DNA repair proteins hABH2, PARP-1, -2, and -4, RAD51B, FANCC, XPA This study;  
 Simbulan-Rosenthal et al., 1999;  
 Jacquemont and Taniguchi, 2007
DNA repair–associated/  
interacting proteins
XPA-binding protein 2, BRCA1/BRCA2-containing  
 complex subunit 45 (prot-BRE), x-ray radiation  
 resistance-associated protein 1
NA
Sister chromatid cohesion N-acetyltransferase ESCO1/EFO1, hSMC5 Potts et al., 2006;  
 Moldovan et al., 2007
Chromatin remodelling and  
DNA-binding proteins
Chromodomain helicase DNA-binding proteins 3–5,  
 p325 subunit of remodeling and spacing factor  
 chromatin–remodelling complex, telomeric repeat–binding  
 protein 2 (TRF2)
Opresko et al., 2004
E3 ubiquitin ligases UHFR1, UHFR2, UBR1, UBR2, ring finger proteins 3, 17,  
 and 151, probable E3 ubiquitin protein ligase MYCBP2
Bronner et al., 2007
Transcription factors TFIIS-L, TFII-I, TFIIE-, sterol regulatory element-binding  
 transcription factor 2 (SREBF2), TFIIIC subunit , TFIID 100 kD  
 subunit (TAF5), TFIIIC 102 kD subunit (TF3C ), transcription  
 factor–like protein MRG15 and X (mortality factor 4–like proteins  
 1 and 2), E2 transcription factor 7
This study
Cell cycle regulators Cell division cycle-associated 2, Bcl2-interacting mediator  
 of cell death, testis spermatocyte apoptosis-related gene 2 protein
NA
Protein kinases Serine/threonine (S/T) protein kinases SRPK1 and -2, 33  
 and MST4, leucine-rich repeat S/T protein kinase 1, STK23  
 (S/T protein kinase 23), S/T protein kinase PLK3,  
 microtubuli-associated S/T protein kinase, microtubuli-associated  
 S/T protein kinase 1, MAPKAP kinase 2 (MK2) and 5 (MK5),  
 mitogen-activated protein kinase 15 (MSK-15)
NA
Methyltransferase H3 lysine 4–specific MLL3, H3-K9 methyltransferase 5,  
 putative rRNA methyltransferase 3
NA
Cancer-associated antigens Melanoma-associated antigen E1 (MAGE E1), MAGE B18,  
 MAGE-G1, natural killer tumor recognition protein (NK-TR),  
 Myc-binding protein–associated protein, Myb-binding  
 protein 1A, hepatoma-derived growth factor–related protein 2  
 isoform1, serologically defined colon cancer antigen 1
NA
RNA polymerase and  
ribosome-associated  
proteins
RNA polymerase II, largest subunit (RPB1), RNA polymerase III  
 subunit 5 (RPC5), RNA polymerase II 140 kD (RPB2), UTP14A U3  
 small nucleolar RNA-associated protein 14 homologue A,  
 60S ribosomal protein L18, 60S ribosomal protein L35,  
 TAF5-like RNA polymerase II p300 (PAF65-beta), mediator of 
 RNA polymerase II  
 transcription subunit 12 homologue
NA
NA, not applicable. Bold indicates proteins localized in replication foci under normal conditions or after DNA damage. The full lists of hits for the APIM and PIP motifs 
are available at http://tare.medisin.ntnu.no/pcna/index.php.
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two-color images. The thickness of the slice was 1 µm. No image process-
ing, except contrast and intensity adjustments, were performed.
Immunofluorescence
HeLa cells were fixed in freshly made 2% paraformaldehyde on ice for 
10 min before cold (20°C) methanol was added, and the cells were 
incubated at 20°C for 20 min. All dilutions and washes were per-
formed in 2% FCS in PBS. The cells were washed (three times for 5 min) 
before addition of 1 µg/ml -PCNA (PC10; Abcam) and incubation for 
1 h at 37°C. Finally, the cells were incubated for 1 h at 37°C with the 
secondary antibody Alexa Fluor 546 goat anti–mouse (diluted 1:2,000; 
Invitrogen). After washing, the cells were analyzed in a laser-scanning 
microscope (LSM 510 Meta; described in the previous paragraph), with 
excitation at 546 nm and detection >560 nm for goat anti–mouse and 
488 nm excitation and detection between 505 and 550 nm for YFP, 
using consecutive scans.
FRET measurements
FRET occurs if the tags (YFP and CFP) are <100 Å (10 nm) apart (Mátyus, 
1992). We detected FRET using the sensitized emission method, measuring 
acceptor (YFP) emission upon donor (CFP) excitation. FRET was scored 
when the intensity of emitted light from YFP after excitation of the CFP fluoro-
chrome was stronger than the light emitted by CFP- or YFP-tagged proteins 
alone after excitation with the YFP and CFP lasers, respectively (bleed 
through), given by the equation FRET = I2  I1 (ID2/ID1)  I3 (IA2/IA3), in 
which I indicates mean intensities. YFP and CFP (vectors only) were used to 
measure background FRET because of dimerization of the tags, and YFP-
PCNA and CFP-PCNA (because PCNA is a homotrimer) were used as posi-
tive control. FRET > 0 was normalized for expression levels using the 
equation NFRET = FRET/(I1 × I3)1/2 (Mátyus, 1992; Xia and Liu, 2001; 
Otterlei et al., 2006). NFRET was calculated from mean intensities within a 
region of interest containing >25 pixels in which all pixels had intensities 
<250, and the mean intensities were between 100 and 200. Channels 1 
(CFP) and 3 (YFP) were measured as described for imaging, and channel 2 
(FRET) was excited with  = 458 nm and detected at  = 530–600 nm. 
ID1–D3 and IA1–A3 were determined for cells transfected with CFP and YFP 
constructs only with the same settings and fluorescence intensities as co-
transfected cells (I1 and I3).
Culture of cell lines and preparation of cell extracts
HeLa (cervical cancer) cells stably expressing the constructs of interest 
were prepared by transfection (Fugene 6) followed by cell sorting or 
cloning by dilution, and prolonged culturing in 400 µg/ml selective 
(using genticine; G418; Invitrogen) high glucose, 4.5 g/liter DME (Bio-
Whittaker) supplemented with 10% FCS, 250 µg/ml amphotericin B 
(Sigma-Aldrich), 100 µg/ml gentamycin (Invitrogen), and 1 mM gluta-
mine (BioWhittaker). The cells were cultured at 37°C in a 5% carbon 
dioxide–humidified atmosphere. Fractionated cell extracts from HeLa 
were prepared by resuspending the cell pellets in 1× packed cell vol-
ume (PCV) in buffer I (10 mM Tris-HCl, pH 8.0, and 50 mM KCl) and 
1× PCV in buffer II (10 mM Tris-HCl, 100 mM KCl, 20% glycerol, 0.5% 
Nonidet P-40, 10 mM EGTA, 10 mM MgCl2, 1 mM DTT, 1× complete 
protease inhibitor [Roche], and phosphatase inhibitor cocktail [PIC I 
and II; Sigma-Aldrich]). Cells were incubated under constant shaking for 
30 min at 4°C, centrifuged at 2,000 rpm, and the supernatant (soluble 
fraction) was harvested. The pellet (containing nuclei) was resuspended 
in 1× PCV of buffer III (10 mM Tris-HCl, pH 8.0, and 100 mM KCl), 1× 
PCV buffer II, and sonicated. The sonicated nuclear pellet was incubated 
with 2 µl DNase/RNase cocktail I (200 U/µl Omnicleave Endonuclease; 
Epicentre Technologies), 1 µl DNase (10 U/µl; Roche), 1 µl bensonase 
(250 U/µl; EMD), 1 µl micrococcal nuclease (100–300 U/mg; Sigma-
Aldrich), and 10 µl RNase (2 mg/ml; Sigma-Aldrich) per 30 mg cell 
extract at 37°C for 1 h. This fraction, denoted chromatin-enriched frac-
tion, was dialyzed against buffer II and III followed by clearance by 
centrifugation before IP.
Figure 4. Point mutations in APIM result in disrupted colocalization and 
reduced FRET. (A) Row 1 shows confocal images of cotransfected WT 
hABH2-CFP, WT hABH2-YFP, and HcRed-PCNA. Rows 2–7 show confocal 
images of the WT proteins with CFP tag (left; green) cotransfected with YFP-
tagged proteins mutated in APIM (middle; green), and HcRed-PCNA (right; 
red) in live cycling HeLa cells. Insets show merged images with PCNA. 
Bar, 5 µm. (B) NFRET calculated for constructs in which single APIM mutation 
does not disrupt colocalization. WT and mutant proteins (YFP fusions of 
TFIIS-L, TFII-I, and Topo II ) are coexpressed with CFP-PCNA. YFP/CFP 
(vectors only) were used as background. Data are the results of two (TFIIS-L 
and TFII-I) to four (Topo II ) independent experiments. Error bars indicate 
mean ± SEM (n = 36–119).
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Sigma-Aldrich), and -Flag (monoclonal; Sigma-Aldrich), as well as the 
secondary antibodies, polyclonal rabbit anti–mouse IgG/HRP and poly-
clonal swine anti–rabbit IgG/HRP (Dako), were diluted in 1% dry milk in 
PBST. The membranes were treated with chemiluminescence reagent 
(SuperSignal West Femto Maximum; Thermo Fisher Scientific), and the pro-
teins were visualized in Image Station (2000R; Kodak).
Dot blot analysis of predicted PCNA-binding peptides
An amino PEG500-UC540 sheet (acid hardened with improved stability) 
containing dots of 28 nmol peptide (stained with Ponceau to visualize the 
spots) was prepared at the peptide synthesis laboratory at The Biotechnol-
ogy Center (University of Oslo, Oslo, Norway). The membrane was probed 
with 1 µg/ml PCNA for 2 h followed by probing with -PCNA (PC10) and 
developed as described for WB. Data extracted from one representative 
dot blot is shown.
Sequence analysis
Details are provided at http://tare.medisin.ntnu.no/pcna/index.php.
MTT assay
HeLa cells stably expressing hABH21–10-YFP and YFP were seeded 
into 96-well plates (4,000 cells/well) and incubated for 3 h. Various 
doses of MMS (Acros Organics), BCNU (1,3-Bis(2-chloroethyl)-1-nitro-
surea; Sigma-Aldrich), TMZ (4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo 
[4.3.0] nona-2,7,9-triene-9-carboxamide; Sigma-Aldrich), and MMC 
(6-amino-1,1a,2,8,8a,8b-hexahydro-8-(hydroxymethyl)-8a-methoxy-5-
methyl-azirino[2’,3:3,4] pyrrolo[1,2-a]indole-4,7-dione carbamate; 
Sigma-Aldrich) were added to the wells. The cells were exposed con-
tinuously until harvest. MTT was added to the cells, the OD was mea-
sured at 570 nm, the mean from at least six wells was used to calculate 
cell survival, and the SD was smaller than the size of the dots. Data 
presented show growth from one representative experiment and has 
been reproduced at least two times.
Clonogenic assay
750 cells were seeded out in 10-cm cell culture dishes in 10 ml growth 
media and grown for 10 d. The cells were fixed in 6% glutaraldehyde in 
PBS for 15 min at room temperature, washed once in PBS, and stained 
with crystal violet, and colony-forming units were counted. Only colonies 
consisting of at least 50 cells were included. Data presented are mean ± 
SD from two (hABH21–7F4A-YFP) and four (hABH21–10-YFP and YFP) inde-
pendent experiments.
Quantitation of 1meA in DNA
HeLa cells stably expressing hABH21–10-YFP and YFP were synchronized by 
the double thymidine block and analyzed by flow cytometry to verify the 
cell cycle phase. The DNA analysis of the cells was performed after metha-
nol fixation (70%), RNase treatment (100 µg/ml in PBS at 37°C for 30 
min), and propidium iodide staining (50 µg/ml in PBS at 37°C for 30 min) 
on an FACS flow cytometer (Canto; BD).
During G1/S arrest, the cells were treated with 1,200 µM MMS 
for 1 h, released, and harvested at defined time points. The cell pellets 
were washed with ice-cold PBS, spun down, snap frozen in liquid N2, and 
stored at 80°C before use. DNA was isolated using DNeasy Blood 
and Tissue kit (QIAGEN). DNA samples were degraded enzymatically 
to deoxynucleosides and analyzed by LC/MS/MS using an HPLC system 
(Prominence; Shimadzu) interfaced with a triple-quadrupole mass spec-
trometer (API5000; Applied Biosystems), essentially as described previously 
(Ringvoll et al., 2006). 1meA and unmodified deoxynucleosides were 
monitored in multiple-reaction monitoring mode using the mass transitions 
266.2→150.1 (1meA), 252.2→136.1 (deoxyadenosine), 243.2→127.1 
(thymidine), 268.2→152.1 (deoxyguanosine), and 228.2→112.1 (deoxy-
cytidine). Quantization was accomplished by comparison with pure deoxy-
nucleoside standards.
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Formaldehyde cross-linking of proteins in intact cells
Cells were harvested and washed twice with cold PBS. 5–6 × 106 cells were 
resuspended in 10 ml PBS containing 0.25% formaldehyde and incubated 
at 37°C for 20 min. Cross-linking was stopped by adding glycine (final con-
centration 0.125 M). Cells were collected by centrifugation and washed 
once in PBS, resuspended in 8× PCV in buffer (20 mM Hepes, pH 7.9, 
1.5 mM MgCl2, 100 mM KCl, 0.2 mM EDTA, 20% glycerol, 0.5% NP-40, 
1 mM DTT, and complete protease inhibitor) containing 5 µl Omnicleave, 
and sonicated. DNase/RNase cocktail I was added, and the homogenate 
was incubated at room temperature for 1 h and dialyzed at 4°C overnight 
in buffer (20 mM Hepes, pH 7.9, 1.5 mM MgCl2, 100 mM KCl, 0.2 mM 
EDTA, 10% glycerol, 1 mM DTT, and complete protease inhibitor).
co-IP
An in-house affinity-purified rabbit polyclonal antibody raised against GFP 
protein, which also recognizes YFP and CFP proteins (called -YFP), and 
monoclonal -PCNA antibody (PC10; Santa Cruz Biotechnology, Inc.) 
were covalently linked to protein A paramagnetic beads (Invitrogen) ac-
cording to instructions provided by New England Biolabs, Inc. 1,500 µg 
total cell–protein of the fractions was incubated with an additional 2 µl 
Omnicleave during IP with 10 µl antibody-coupled beads under constant 
rotation at 4°C over night (IP). The beads were washed four times with 200 µl 
10 mM Tris-HCl and 50 mM KCl, pH 8, with a 5-min incubation on ice 
in between. The beads were resuspended in NuPAGE (Invitrogen) loading 
buffer and 1 mM DTT, heated, and the IP elutions were separated on 
4–12% Bis-Tris-HCl (NuPAGE) gels. 50 µg cell extract was used for input.
IP of cross-linked protein extracts
Cross-linked Flag fusion proteins were immunoprecipitated using anti-Flag 
M2 affinity gel (herein referred to as -Flag; Sigma-Aldrich) according to 
the manufacturer’s protocol. The resin was prepared by washing once with 
0.1 M glycine and 0.5 M NaCl, pH 3.0, and three times with TBS buffer 
(50 mM Tris HCl, pH 7.4, 150 mM NaCl, 10 mM Na butyrate, and 
20 mM NaF). 2.5 mg and 5 mg (hABH21–7-YFP and hABH21–7F4A-YFP, 
respectively) of cross-linked extracts were incubated with 20 µl or 40 µl 
resin, respectively (packed gel volume), for 2 h at 4°C under constant rota-
tion. The resin was washed three times with 500 µl of TBS buffer, and the 
cross-linked Flag fusion proteins were eluted by incubating the resin with 
100 µl 3× Flag peptide in TBS buffer (final concentration of 450 ng/µl) for 
30 min at 4°C under constant rotation. The cross-linking was reversed by 
a 30-min incubation at 95°C. For further WB analyses, the IP elution frac-
tions were heated in 1× LDS sample buffer (NuPAGE) and 0.1 M DTT 
(65°C for 10 min) before loading 4–12% Bis-Tris-HCl (NuPAGE) gels.
2D gel electrophoresis
Immunoprecipitates of cross-linked extracts of hABH21–7YFP–3× Flag 
(5 mg) and hABH21–7F4A-YFP-3× Flag (10 mg) pulled down with -Flag 
resin (40 µl and 80 µl, respectively) and by magnetic -PCNA–coupled 
beads (50 µl beads; 2 mg extract) was subjected to 2D Western analysis. 
The resin was washed three times with 500 µl of TBS buffer. The resin was 
washed once in 20 mM Tris HCl, pH 7.4, 50 mM NaCl, 10 mM Na buty-
rate, and 20 mM NaF, and the cross-linked Flag fusion proteins were eluted 
by incubating the resin with 100 µl 3×Flag peptide in this buffer (final con-
centration of 450 ng/µl) for 30 min at 4°C under constant rotation. First di-
mension: after IP and elution, the cross-links were reversed (see previous 
paragraph), the -PCNA beads were washed three times with 10 mM Tris-HCl 
and 50 mM KCl (1 ml), and resuspended in 340 µl destreak with 1% 
IPG buffer, pH 4–7 (GE Healthcare). After incubation overnight in a shaker 
at 4°C, the elutions were collected in separate vials without -PCNA 
beads. 20 ng recombinant RAD51 protein (molecular mass, 37 kD; 
pI, 5.4; provided by I. Hickson Weatherall, University of Oxford, Oxford, 
England, UK) was added to each sample to serve as an internal standard. 
The samples were used to rehydrate immobiline DryStrips (18 cm; pH 4–7; 
GE Healthcare) overnight. The isoelectric focusing was performed accord-
ing to the manufacturer’s instructions in the IPGphor II unit (GE Healthcare). 
After isoelectric focusing, strips were cut after pH 5.5, and the pieces from 
pH 4–5.5 were incubated in equilibrium buffer (50 mM Tris-HCl, pH 8.8, 
6 M urea, 30% glycerol, and 2% SDS) containing 1% DTT for 15 min fol-
lowed by a 15-min incubation in the same buffer containing 2.5% iodo-
acetamide instead of DTT. Second dimension: the strips were loaded onto 
NuPAGE Novex 4–12% gels (Invitrogen).
WB
After gel electrophoresis, the polyvinylidene fluoride membranes (Immobi-
lon; Millipore) were blocked in 5% low fat dry milk in PBST (PBS with 0.1% 
Tween 20). The primary antibodies, -PCNA (PC10), -hABH2 (monoclonal; 
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